1
|
Savitskii MV, Moskaleva NE, Brito A, Markin PA, Zigangirova NA, Soloveva AV, Sheremet AB, Bondareva NE, Lubenec NL, Tagliaro F, Tarasov VV, Tatzhikova KA, Appolonova SA. Pharmacokinetics, tissue distribution, bioavailability and excretion of the anti-virulence drug Fluorothiazinon in rats and rabbits. J Antibiot (Tokyo) 2024:10.1038/s41429-024-00719-1. [PMID: 38491136 DOI: 10.1038/s41429-024-00719-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 01/15/2024] [Accepted: 03/06/2024] [Indexed: 03/18/2024]
Abstract
Growing antimicrobial resistance has accelerated the development of anti-virulence drugs to suppress bacterial toxicity without affecting cell viability. Fluorothiazinon (FT), an anti-virulence, type three secretion system and flagella motility inhibitor which has shown promise to suppress drug-resistant pathogens having the potential to enhance the efficacy of commonly prescribed antibiotics when used in combination. In this study we characterized the pharmacokinetics, tissue distribution, bioavailability and excretion of FT in rats and rabbits. FT presented a dose-proportional linear increase in the blood of rats. Tissue distribution profiling confirmed that FT distributes to all organs being substantially higher than in the blood of rats. The bioavailability of FT was higher when administered with starch than with water implying FT should be ideally dosed with food. FT was primarily excreted in the feces in rats and rabbits while negligible amounts are recovered from the urine.
Collapse
Affiliation(s)
- Mark V Savitskii
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
- Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
- Unit of Forensic Medicine, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
| | - Natalia E Moskaleva
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
- World Class Research Center Digital Biodesign and Personalized Healthcare, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
| | - Alex Brito
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| | - Pavel A Markin
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| | - Nailya A Zigangirova
- National Research Center for Epidemiology and Microbiology named after N. F. Gamaleya, Russian Health Ministry, Moscow, Russian Federation
| | - Anna V Soloveva
- National Research Center for Epidemiology and Microbiology named after N. F. Gamaleya, Russian Health Ministry, Moscow, Russian Federation
| | - Anna B Sheremet
- National Research Center for Epidemiology and Microbiology named after N. F. Gamaleya, Russian Health Ministry, Moscow, Russian Federation
| | - Natalia E Bondareva
- National Research Center for Epidemiology and Microbiology named after N. F. Gamaleya, Russian Health Ministry, Moscow, Russian Federation
| | - Nadezhda L Lubenec
- National Research Center for Epidemiology and Microbiology named after N. F. Gamaleya, Russian Health Ministry, Moscow, Russian Federation
| | - Franco Tagliaro
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
- Unit of Forensic Medicine, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
| | - Vadim V Tarasov
- Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| | - Kristina A Tatzhikova
- Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| | - Svetlana A Appolonova
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
- Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
| |
Collapse
|
2
|
Namiot ED, Smirnovová D, Sokolov AV, Chubarev VN, Tarasov VV, Schiöth HB. The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs. Front Pharmacol 2023; 14:1228148. [PMID: 37790806 PMCID: PMC10544909 DOI: 10.3389/fphar.2023.1228148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 08/31/2023] [Indexed: 10/05/2023] Open
Abstract
Introduction: Clinical trials are the gold standard for testing new therapies. Databases like ClinicalTrials.gov provide access to trial information, mainly covering the US and Europe. In 2006, WHO introduced the global ICTRP, aggregating data from ClinicalTrials.gov and 17 other national registers, making it the largest clinical trial platform by June 2019. This study conducts a comprehensive global analysis of the ICTRP database and provides framework for large-scale data analysis, data preparation, curation, and filtering. Materials and methods: The trends in 689,793 records from the ICTRP database (covering trials registered from 1990 to 2020) were analyzed. Records were adjusted for duplicates and mapping of agents to drug classes was performed. Several databases, including DrugBank, MESH, and the NIH Drug Information Portal were used to investigate trends in agent classes. Results: Our novel approach unveiled that 0.5% of the trials we identified were hidden duplicates, primarily originating from the EUCTR database, which accounted for 82.9% of these duplicates. However, the overall number of hidden duplicates within the ICTRP seems to be decreasing. In total, 689 793 trials (478 345 interventional) were registered in the ICTRP between 1990 and 2020, surpassing the count of trials in ClinicalTrials.gov (362 500 trials by the end of 2020). We identified 4 865 unique agents in trials with DrugBank, whereas 2 633 agents were identified with NIH Drug Information Portal data. After the ClinicalTrials.gov, EUCTR had the most trials in the ICTRP, followed by CTRI, IRCT, CHiCTR, and ISRCTN. CHiCTR displayed a significant surge in trial registration around 2015, while CTRI experienced rapid growth starting in 2016. Conclusion: This study highlights both the strengths and weaknesses of using the ICTRP as a data source for analyzing trends in clinical trials, and emphasizes the value of utilizing multiple registries for a comprehensive analysis.
Collapse
Affiliation(s)
- Eugenia D. Namiot
- Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| | - Diana Smirnovová
- Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| | - Aleksandr V. Sokolov
- Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| | | | - Vadim V. Tarasov
- Advanced Molecular Technology, Limited Liable Company (LLC), Moscow, Russia
| | - Helgi B. Schiöth
- Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| |
Collapse
|
3
|
Zobdeh F, Eremenko II, Akan MA, Tarasov VV, Chubarev VN, Schiöth HB, Mwinyi J. The Epigenetics of Migraine. Int J Mol Sci 2023; 24:ijms24119127. [PMID: 37298078 DOI: 10.3390/ijms24119127] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 05/05/2023] [Accepted: 05/11/2023] [Indexed: 06/12/2023] Open
Abstract
Migraine is a complex neurological disorder and a major cause of disability. A wide range of different drug classes such as triptans, antidepressants, anticonvulsants, analgesics, and beta-blockers are used in acute and preventive migraine therapy. Despite a considerable progress in the development of novel and targeted therapeutic interventions during recent years, e.g., drugs that inhibit the calcitonin gene-related peptide (CGRP) pathway, therapy success rates are still unsatisfactory. The diversity of drug classes used in migraine therapy partly reflects the limited perception of migraine pathophysiology. Genetics seems to explain only to a minor extent the susceptibility and pathophysiological aspects of migraine. While the role of genetics in migraine has been extensively studied in the past, the interest in studying the role of gene regulatory mechanisms in migraine pathophysiology is recently evolving. A better understanding of the causes and consequences of migraine-associated epigenetic changes could help to better understand migraine risk, pathogenesis, development, course, diagnosis, and prognosis. Additionally, it could be a promising avenue to discover new therapeutic targets for migraine treatment and monitoring. In this review, we summarize the state of the art regarding epigenetic findings in relation to migraine pathogenesis and potential therapeutic targets, with a focus on DNA methylation, histone acetylation, and microRNA-dependent regulation. Several genes and their methylation patterns such as CALCA (migraine symptoms and age of migraine onset), RAMP1, NPTX2, and SH2D5 (migraine chronification) and microRNA molecules such as miR-34a-5p and miR-382-5p (treatment response) seem especially worthy of further study regarding their role in migraine pathogenesis, course, and therapy. Additionally, changes in genes including COMT, GIT2, ZNF234, and SOCS1 have been linked to migraine progression to medication overuse headache (MOH), and several microRNA molecules such as let-7a-5p, let-7b-5p, let-7f-5p, miR-155, miR-126, let-7g, hsa-miR-34a-5p, hsa-miR-375, miR-181a, let-7b, miR-22, and miR-155-5p have been implicated with migraine pathophysiology. Epigenetic changes could be a potential tool for a better understanding of migraine pathophysiology and the identification of new therapeutic possibilities. However, further studies with larger sample sizes are needed to verify these early findings and to be able to establish epigenetic targets as disease predictors or therapeutic targets.
Collapse
Affiliation(s)
- Farzin Zobdeh
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Husargatan 3, P.O. Box 593, 75124 Uppsala, Sweden
| | - Ivan I Eremenko
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Husargatan 3, P.O. Box 593, 75124 Uppsala, Sweden
- Advanced Molecular Technology, LLC, 354340 Moscow, Russia
| | - Mikail A Akan
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Husargatan 3, P.O. Box 593, 75124 Uppsala, Sweden
- Advanced Molecular Technology, LLC, 354340 Moscow, Russia
| | | | | | - Helgi B Schiöth
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Husargatan 3, P.O. Box 593, 75124 Uppsala, Sweden
| | - Jessica Mwinyi
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Husargatan 3, P.O. Box 593, 75124 Uppsala, Sweden
| |
Collapse
|
4
|
Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Liu W, Schiöth HB. Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules. Front Pharmacol 2022; 13:1057083. [PMID: 36506513 PMCID: PMC9731127 DOI: 10.3389/fphar.2022.1057083] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Accepted: 11/04/2022] [Indexed: 11/25/2022] Open
Abstract
The phosphodiesterase (PDE) enzymes, key regulator of the cyclic nucleotide signal transduction system, are long-established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a particularly high number of clinical trials involving PDE inhibitors, prompting us to further evaluate the current status of this class of therapeutic agents. In total, we have identified 87 agents with PDE-inhibiting capacity, of which 85 interact with PDE enzymes as primary target. We provide an overview of the clinical drug development with focus on the current clinical uses, novel molecules and indications, highlighting relevant clinical studies. We found that the bulk of current clinical uses for this class of therapeutic agents are chronic obstructive pulmonary disease (COPD), vascular and cardiovascular disorders and inflammatory skin conditions. In COPD, particularly, PDE inhibitors are characterised by the compliance-limiting adverse reactions. We discuss efforts directed to appropriately adjusting the dose regimens and conducting structure-activity relationship studies to determine the effect of structural features on safety profile. The ongoing development predominantly concentrates on central nervous system diseases, such as schizophrenia, Alzheimer's disease, Parkinson's disease and fragile X syndrome; notable advancements are being also made in mycobacterial infections, HIV and Duchenne muscular dystrophy. Our analysis predicts the diversification of PDE inhibitors' will continue to grow thanks to the molecules in preclinical development and the ongoing research involving drugs in clinical development.
Collapse
Affiliation(s)
- Andrey D. Bondarev
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| | - Misty M. Attwood
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| | - Jörgen Jonsson
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| | | | | | - Wen Liu
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| | - Helgi B. Schiöth
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden,*Correspondence: Helgi B. Schiöth,
| |
Collapse
|
5
|
Nazarova VA, Sokolov AV, Chubarev VN, Tarasov VV, Schiöth HB. Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol 2022; 13:1066988. [PMID: 36467081 PMCID: PMC9713849 DOI: 10.3389/fphar.2022.1066988] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 11/01/2022] [Indexed: 07/30/2023] Open
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders having a high influence on social interactions. The number of approved treatments and clinical trials for ADHD have increased markedly during the recent decade. This analytical review provides a quantitative overview of the existing pharmacological and non-pharmacological methods of ADHD treatments investigated in clinical trials during 1999-2021. A total of 695 interventional trials were manually assessed from clinicaltrial.gov with the search term « ADHD», and trial data has been used for analysis. A clear majority of the studies investigated non-pharmacological therapies (∼80%), including many behavioral options, such as social skills training, sleep and physical activity interventions, meditation and hypnotherapy. Devices, complementary and other alternative methods of ADHD treatment are also gaining attention. The pharmacological group accounts for ∼20% of all the studies. The most common drug classes include central nervous system stimulants (e.g., methylphenidate hydrochloride, lisdexamfetamine dimesylate, amphetamine sulfate, mixed amphetamine salts, a combination of dexmethylphenidate hydrochloride and serdexmethylphenidate chloride), selective noradrenaline reuptake inhibitors (atomoxetine, viloxazine), and alpha2 adrenergic receptor agonists (guanfacine hydrochloride, clonidine hydrochloride). Several studies investigated antidepressants (e.g., bupropion hydrochloride, vortioxetine), and atypical antipsychotics (e.g., quetiapine, aripiprazole) but these are yet not approved by the FDA for ADHD treatment. We discuss the quantitative trends in clinical trials and provide an overview of the new drug agents and non-pharmacological therapies, drug targets, and novel treatment options.
Collapse
Affiliation(s)
- Victoria A. Nazarova
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| | - Aleksandr V. Sokolov
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| | | | | | - Helgi B. Schiöth
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden
| |
Collapse
|
6
|
Klyucherev TO, Olszewski P, Shalimova AA, Chubarev VN, Tarasov VV, Attwood MM, Syvänen S, Schiöth HB. Advances in the development of new biomarkers for Alzheimer's disease. Transl Neurodegener 2022; 11:25. [PMID: 35449079 PMCID: PMC9027827 DOI: 10.1186/s40035-022-00296-z] [Citation(s) in RCA: 51] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Accepted: 03/28/2022] [Indexed: 12/16/2022] Open
Abstract
Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most common type of neurodegenerative dementia. The prevalence of AD is expected to increase as the population ages, placing an additional burden on national healthcare systems. There is a large need for new diagnostic tests that can detect AD at an early stage with high specificity at relatively low cost. The development of modern analytical diagnostic tools has made it possible to determine several biomarkers of AD with high specificity, including pathogenic proteins, markers of synaptic dysfunction, and markers of inflammation in the blood. There is a considerable potential in using microRNA (miRNA) as markers of AD, and diagnostic studies based on miRNA panels suggest that AD could potentially be determined with high accuracy for individual patients. Studies of the retina with improved methods of visualization of the fundus are also showing promising results for the potential diagnosis of the disease. This review focuses on the recent developments of blood, plasma, and ocular biomarkers for the diagnosis of AD.
Collapse
Affiliation(s)
- Timofey O Klyucherev
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden.,Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Pawel Olszewski
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden
| | - Alena A Shalimova
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden.,Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vladimir N Chubarev
- Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vadim V Tarasov
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.,Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Misty M Attwood
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden
| | - Stina Syvänen
- Department of Public Health and Caring Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
| | - Helgi B Schiöth
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden.
| |
Collapse
|
7
|
Mikhaylenko DS, Kuznetsova EB, Musatova VV, Bure IV, Deryagina TA, Alekseeva EA, Tarasov VV, Zamyatnin AA, Nemtsova MV. Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis. J Pers Med 2022; 12:jpm12040641. [PMID: 35455757 PMCID: PMC9024465 DOI: 10.3390/jpm12040641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 04/12/2022] [Accepted: 04/13/2022] [Indexed: 11/16/2022] Open
Abstract
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease and its treatment is an urgent problem of rheumatology. Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 and is one of the few promising drugs for RA therapy. One-hundred-and-twenty-five DNA samples from Russian patients with RA, treated with olokizumab, were genotyped with an NGS panel containing 60 single nucleotide polymorphisms (SNPs) and the whole coding sequences of IL6, IL6R, TNFRSF1A, CTLA4, IL10, IL23R, and PADI4; and by RT-PCR for HLA-DRB1 and HLA-B. Associations of polymorphic variants with olokizumab efficacy according to the scores ACR20, ACR50, and DAS28-CRP were determined. We analyzed the obtained data by using logistic regression, ROC curves, and multivariate ANOVA. A high predictive value of the response to olokizumab therapy at 24 weeks was found for the combination of HLA-DRB1*04 and HLA-B*27 alleles with SNPs located in non-HLA genes (IL1B, IL17A, PADI4, DHODH, GLCCI1, IL23R, and TNFAIP3), and clinical characteristics (age, RA duration, and intensity) according to ACR20. Thus, the comprehensive assessment of polymorphic variants of HLA and non-HLA genes considering population characteristics in combination with clinical parameters allows for the elaboration of an RA prognostic panel.
Collapse
Affiliation(s)
- Dmitry S. Mikhaylenko
- Laboratory of Medical Genetics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (D.S.M.); (E.B.K.); (I.V.B.); (E.A.A.); (M.V.N.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, 115522 Moscow, Russia; (V.V.M.); (T.A.D.)
| | - Ekaterina B. Kuznetsova
- Laboratory of Medical Genetics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (D.S.M.); (E.B.K.); (I.V.B.); (E.A.A.); (M.V.N.)
| | - Viktoria V. Musatova
- Laboratory of Epigenetics, Research Centre for Medical Genetics, 115522 Moscow, Russia; (V.V.M.); (T.A.D.)
| | - Irina V. Bure
- Laboratory of Medical Genetics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (D.S.M.); (E.B.K.); (I.V.B.); (E.A.A.); (M.V.N.)
| | - Tatiana A. Deryagina
- Laboratory of Epigenetics, Research Centre for Medical Genetics, 115522 Moscow, Russia; (V.V.M.); (T.A.D.)
| | - Ekaterina A. Alekseeva
- Laboratory of Medical Genetics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (D.S.M.); (E.B.K.); (I.V.B.); (E.A.A.); (M.V.N.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, 115522 Moscow, Russia; (V.V.M.); (T.A.D.)
| | - Vadim V. Tarasov
- Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia;
| | - Andrey A. Zamyatnin
- Laboratory of Medical Genetics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (D.S.M.); (E.B.K.); (I.V.B.); (E.A.A.); (M.V.N.)
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia
- Department of Biotechnology, Sirius University of Science and Technology, 1 Olympic Ave, 354340 Sochi, Russia
- Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7X, UK
- Correspondence: ; Tel.: +7-9261180220
| | - Marina V. Nemtsova
- Laboratory of Medical Genetics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (D.S.M.); (E.B.K.); (I.V.B.); (E.A.A.); (M.V.N.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, 115522 Moscow, Russia; (V.V.M.); (T.A.D.)
| |
Collapse
|
8
|
Rezaei M, Danilova ND, Soltani M, Savvateeva LV, V Tarasov V, Ganjalikhani-Hakemi M, V Bazhinf A, A Zamyatnin A. Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities. Curr Cancer Drug Targets 2022; 22:437-453. [PMID: 35156572 DOI: 10.2174/1568009622666220214103533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 12/21/2021] [Accepted: 12/31/2021] [Indexed: 11/22/2022]
Abstract
The idea of cancer immunotherapy is to stimulate the immune system to fight tumors without destroying normal cells. One of the anticancer therapy methods, among many, is based on the use of cancer vaccines that contain tumor antigens in order to induce immune responses against tumors. However, clinical trials have shown that the use of such vaccines as a monotherapy is ineffective in many cases, since they do not cause a strong immune response. Particular tumors are resistant to immunotherapy due to the absence or insufficient infiltration of tumors with CD8+ T cells, and hence, they are called cold or non-inflamed tumors. Cold tumors are characterized by a lack of CD8+ T cell infiltration, the presence of anti-inflammatory myeloid cells, tumor-associated M2 macrophages, and regulatory T cells. It is very important to understand which stage of the antitumor response does not work properly in order to use the right strategy for the treatment of patients. Applying other therapeutic methods alongside cancer vaccines can be more rational for cold tumors which do not provoke the immune system strongly. Herein, we indicate some combinational therapies that have been used or are in progress for cold tumor treatment alongside vaccines.
Collapse
Affiliation(s)
- Mahnaz Rezaei
- Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | | | - Mozhdeh Soltani
- Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Lyudmila V Savvateeva
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vadim V Tarasov
- Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Mazdak Ganjalikhani-Hakemi
- Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
- Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Alexandr V Bazhinf
- Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians University of Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
| | - Andrey A Zamyatnin
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russia
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
- Department of Biotechnology, Sirius University of Science and Technology, Sochi, Russia
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK
| |
Collapse
|
9
|
Belyaeva II, Subbotina AG, Eremenko II, Tarasov VV, Chubarev VN, Schiöth HB, Mwinyi J. Pharmacogenetics in Primary Headache Disorders. Front Pharmacol 2022; 12:820214. [PMID: 35222013 PMCID: PMC8866828 DOI: 10.3389/fphar.2021.820214] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Accepted: 12/23/2021] [Indexed: 11/09/2022] Open
Abstract
Primary headache disorders, such as migraine, tension-type headache (TTH), and cluster headache, belong to the most common neurological disorders affecting a high percentage of people worldwide. Headache induces a high burden for the affected individuals on the personal level, with a strong impact on life quality, daily life management, and causes immense costs for the healthcare systems. Although a relatively broad spectrum of different pharmacological classes for the treatment of headache disorders are available, treatment effectiveness is often limited by high variances in therapy responses. Genetic variants can influence the individual treatment success by influencing pharmacokinetics or pharmacodynamics of the therapeutic as investigated in the research field of pharmacogenetics. This review summarizes the current knowledge on important primary headache disorders, including migraine, TTH, and cluster headache. We also summarize current acute and preventive treatment options for the three headache disorders based on drug classes and compounds taking important therapy guidelines into consideration. Importantly, the work summarizes and discusses the role of genetic polymorphisms regarding their impact on metabolism safety and the effect of therapeutics that are used to treat migraine, cluster headache, and TTH exploring drug classes such as nonsteroidal anti-inflammatory drugs, triptans, antidepressants, anticonvulsants, calcium channel blockers, drugs with effect on the renin-angiotensin system, and novel headache therapeutics such as ditans, anti-calcitonin-gene-related peptide antibodies, and gepants. Genetic variants in important phase I-, II-, and III-associated genes such as cytochrome P450 genes, UGT genes, and different transporter genes are scrutinized as well as variants in genes important for pharmacodynamics and several functions outside the pharmacokinetic and pharmacodynamic spectrum. Finally, the article evaluates the potential and limitations of pharmacogenetic approaches for individual therapy adjustments in headache disorders.
Collapse
Affiliation(s)
- Irina I. Belyaeva
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden,Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Anna G. Subbotina
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden,Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Ivan I. Eremenko
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden,Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vadim V. Tarasov
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia,Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vladimir N. Chubarev
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Helgi B. Schiöth
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden,Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Jessica Mwinyi
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden,*Correspondence: Jessica Mwinyi,
| |
Collapse
|
10
|
Sokolov AV, Dostdar SA, Attwood MM, Krasilnikova AA, Ilina AA, Nabieva AS, Lisitsyna AA, Chubarev VN, Tarasov VV, Schiöth HB. Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies. Pharmacol Rev 2021; 73:1-32. [PMID: 34663683 DOI: 10.1124/pharmrev.121.000317] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Brain cancer is a formidable challenge for drug development, and drugs derived from many cutting-edge technologies are being tested in clinical trials. We manually characterized 981 clinical trials on brain tumors that were registered in ClinicalTrials.gov from 2010 to 2020. We identified 582 unique therapeutic entities targeting 581 unique drug targets and 557 unique treatment combinations involving drugs. We performed the classification of both the drugs and drug targets based on pharmacological and structural classifications. Our analysis demonstrates a large diversity of agents and targets. Currently, we identified 32 different pharmacological directions for therapies that are based on 42 structural classes of agents. Our analysis shows that kinase inhibitors, chemotherapeutic agents, and cancer vaccines are the three most common classes of agents identified in trials. Agents in clinical trials demonstrated uneven distribution in combination approaches; chemotherapy agents, proteasome inhibitors, and immune modulators frequently appeared in combinations, whereas kinase inhibitors, modified immune effector cells did not as was shown by combination networks and descriptive statistics. This analysis provides an extensive overview of the drug discovery field in brain cancer, shifts that have been happening in recent years, and challenges that are likely to come. SIGNIFICANCE STATEMENT: This review provides comprehensive quantitative analysis and discussion of the brain cancer drug discovery field, including classification of drug, targets, and therapies.
Collapse
Affiliation(s)
- Aleksandr V Sokolov
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Samira A Dostdar
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Misty M Attwood
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Aleksandra A Krasilnikova
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Anastasia A Ilina
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Amina Sh Nabieva
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Anna A Lisitsyna
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vladimir N Chubarev
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vadim V Tarasov
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Helgi B Schiöth
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| |
Collapse
|
11
|
Zobdeh F, Ben Kraiem A, Attwood MM, Chubarev VN, Tarasov VV, Schiöth HB, Mwinyi J. Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol 2021; 178:4588-4607. [PMID: 34379793 DOI: 10.1111/bph.15657] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 07/28/2021] [Accepted: 08/02/2021] [Indexed: 11/26/2022] Open
Abstract
Migraine is the sixth most prevalent disease globally, a major cause of disability, and it imposes an enormous personal and socioeconomic burden. Migraine treatment is often limited by insufficient therapy response, leading to the need for individually adjusted treatment approaches. In this review, we analyse historical and current pharmaceutical development approaches in acute and chronic migraine based on a comprehensive and systematic analysis of Food and Drug Administration (FDA)-approved drugs and those under investigation. The development of migraine therapeutics has significantly intensified during the last 3 years, as shown by our analysis of the trends of drug development between 1970 and 2020. The spectrum of drug targets has expanded considerably, which has been accompanied by an increase in the number of specialised clinical trials. This review highlights the mechanistic implications of FDA-approved and currently investigated drugs and discusses current and future therapeutic options based on identified drug classes of interest.
Collapse
Affiliation(s)
- Farzin Zobdeh
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.,Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden
| | - Aziza Ben Kraiem
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.,Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden
| | - Misty M Attwood
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden
| | - Vladimir N Chubarev
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vadim V Tarasov
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.,Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Helgi B Schiöth
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden.,Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Jessica Mwinyi
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, Sweden
| |
Collapse
|
12
|
Nikolenko VN, Oganesyan MV, Vovkogon AD, Nikitina AT, Sozonova EA, Kudryashova VA, Rizaeva NA, Cabezas R, Avila-Rodriguez M, Neganova ME, Mikhaleva LM, Bachurin SO, Somasundaram SG, Kirkland CE, Tarasov VV, Aliev G. Current Understanding of Central Nervous System Drainage Systems: Implications in the Context of Neurodegenerative Diseases. Curr Neuropharmacol 2021; 18:1054-1063. [PMID: 31729299 PMCID: PMC7709156 DOI: 10.2174/1570159x17666191113103850] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Revised: 10/15/2019] [Accepted: 11/10/2019] [Indexed: 12/19/2022] Open
Abstract
Until recently, it was thought that there were no lymphatic vessels in the central nervous system (CNS). Therefore, all metabolic processes were assumed to take place only in the circulation of the cerebrospinal fluid (CSF) and through the blood-brain barrier's (BBB), which regulate ion transport and ensure the functioning of the CNS. However, recent findings yield a new perspective: There is an exchange of CSF with interstitial fluid (ISF), which is drained to the paravenous space and reaches lymphatic nodes at the end. This circulation is known as the glymphatic system. The glymphatic system is an extensive network of meningeal lymphatic vessels (MLV) in the basal area of the skull that provides another path for waste products from CNS to reach the bloodstream. MLV develop postnatally, initially appearing around the foramina in the basal part of the skull and the spinal cord, thereafter sprouting along the skull's blood vessels and spinal nerves in various areas of the meninges. VEGF-C protein (vascular endothelial growth factor), expressed mainly by vascular smooth cells, plays an important role in the development of the MLV. The regenerative potential and plasticity of MLV and the novel discoveries related to CNS drainage offer potential for the treatment of neurodegenerative diseases such as dementia, hydrocephalus, stroke, multiple sclerosis, and Alzheimer disease (AD). Herein, we present an overview of the structure and function of the glymphatic system and MLV, and their potential involvement in the pathology and progression of neurodegenerative diseases.
Collapse
Affiliation(s)
- Vladimir N Nikolenko
- Department of Human Anatomy, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia,Department of Normal and Topographic Anatomy, Federal State Budget Educational Institution of Higher Education M.V. Lomonosov Moscow State University, Leninskie Gory, 1, Moscow, 119991, Russia
| | - Marine V Oganesyan
- Department of Human Anatomy, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia
| | - Angela D Vovkogon
- Department of Human Anatomy, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia
| | - Arina T Nikitina
- Department of Human Anatomy, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia
| | - Ekaterina A Sozonova
- Department of Human Anatomy, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia
| | - Valentina A Kudryashova
- Department of Human Anatomy, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia
| | - Negoria A Rizaeva
- Department of Human Anatomy, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia
| | - Ricardo Cabezas
- Department of Biochemistry and Nutrition, Science Faculty, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Marco Avila-Rodriguez
- Health Sciences Faculty, Clinic Sciences Department, University of Tolima, 730006 Ibague, Colombia
| | - Margarita E Neganova
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow Region, 142432, Russia
| | - Liudmila M Mikhaleva
- Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow, 117418, Russian Federation
| | - Sergey O Bachurin
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow Region, 142432, Russia
| | | | - Cecil E Kirkland
- Department of Biological Sciences, Salem University, Salem, WV, USA
| | - Vadim V Tarasov
- Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia
| | - Gjumrakch Aliev
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow Region, 142432, Russia,Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow, 117418, Russian Federation,Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia,GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, USA
| |
Collapse
|
13
|
Tarasov VV, Ivanets NN, Svistunov AA, Chubarev VN, Kinkulkina MA, Tikhonova YG, Syzrantsev NS, Chubarev IV, Muresanu C, Somasundaram SG, Kirkland CE, Aliev G. Biological mechanisms of atypical and melancholic major depressive disorder. Curr Pharm Des 2021; 27:3399-3412. [PMID: 34082674 DOI: 10.2174/1381612827666210603145441] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Accepted: 03/17/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND This review summarizes recent findings in molecular biology and neuroimaging and their applicability to the classification and identification of depression. We discuss whether there is reliable evidence that could become a basis for biomarkers or subtyping that may enhance our understanding of the biological foundations of depression and may be useful for clinical practice with respect to diagnosis and prognosis as well as the selection of treatments. OBJECTIVE The purpose of this investigation is to present molecular mechanisms that contribute to different origins of depressions that could prove useful in daily psychiatric clinic based practices. METHOD The authors analyzed and summarized electronic publications available via PubMed, Science Direct, Google Scholar, and Scopus. RESULTS The introduction of molecular diagnostics methods into medical practice is a promising method to improve the accuracy of the diagnosis of depression in clinical settings. The literature analysis revealed structural changes in some areas of the brain, its neuroplasticity, as well as changes at the molecular, epigenetic, and genetic levels. However, there are no current reliable biomarkers for differential diagnosis of the types and subtypes of depression. CONCLUSION Major depressive disorder is a biologically and genetically heterogeneous disorder. Given its complexity, subtyping is worthwhile to identify biological bases of conditions. The literature review provides ample findings that reveal possible underlying biological mechanisms associated with atypical and melancholic depression. Additional, focused research should be continued with respect to the molecular and genetic biology of different types of depression. There already are promising findings, but additional research to define biologically based depressive subtypes is needed and worthwhile.
Collapse
Affiliation(s)
- Vadim V Tarasov
- I. M. Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskayast., Moscow 119991. Russian Federation
| | - Nikolay N Ivanets
- I. M. Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskayast., Moscow 119991. Russian Federation
| | - Andrey A Svistunov
- I. M. Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskayast., Moscow 119991. Russian Federation
| | - Vladimir N Chubarev
- I. M. Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskayast., Moscow 119991. Russian Federation
| | - Marina A Kinkulkina
- I. M. Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskayast., Moscow 119991. Russian Federation
| | - Yuliya G Tikhonova
- I. M. Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskayast., Moscow 119991. Russian Federation
| | - Nikita S Syzrantsev
- I. M. Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskayast., Moscow 119991. Russian Federation
| | - Ivan V Chubarev
- Mental Health Research Center, Moscow, 115552 . Russian Federation
| | - Cristian Muresanu
- Research Center for Applied Biotechnology in Diagnosis and Molecular Therapies (BIODIATECH), Str. Trifoiuluinr. 12 G, 400478, Cluj-Napoca. Romania
| | - Siva G Somasundaram
- Department of Biological Sciences, Salem University, Salem, WV, United States
| | - Cecil E Kirkland
- Department of Biological Sciences, Salem University, Salem, WV, United States
| | - Gjumrakch Aliev
- I. M. Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskayast., Moscow 119991. Russian Federation
| |
Collapse
|
14
|
Shalimova A, Babasieva V, Chubarev VN, Tarasov VV, Schiöth HB, Mwinyi J. Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics 2021; 22:485-503. [PMID: 34018822 DOI: 10.2217/pgs-2020-0157] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Major depressive disorder is connected with high rates of functional disability and mortality. About a third of the patients are at risk of therapy failure. Several pharmacogenetic markers especially located in CYP450 genes such as CYP2D6 or CYP2C19 are of relevance for therapy outcome prediction in major depressive disorder but a further optimization of predictive tools is warranted. The article summarizes the current knowledge on pharmacogenetic variants, therapy effects and side effects of important antidepressive therapeutics, and sheds light on new methodological approaches for therapy response estimation based on genetic markers with relevance for pharmacokinetics, pharmacodynamics and disease pathology identified in genome-wide association study analyses, highlighting polygenic risk score analysis as a tool for further optimization of individualized therapy outcome prediction.
Collapse
Affiliation(s)
- Alena Shalimova
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, 751 24, Sweden.,Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia
| | - Viktoria Babasieva
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, 751 24, Sweden.,Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia
| | - Vladimir N Chubarev
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia
| | - Vadim V Tarasov
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia.,Institute of Translational Medicine & Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia
| | - Helgi B Schiöth
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, 751 24, Sweden.,Institute of Translational Medicine & Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia
| | - Jessica Mwinyi
- Department of Neuroscience, Functional Pharmacology, University of Uppsala, Uppsala, 751 24, Sweden
| |
Collapse
|
15
|
Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schiöth HB. Recent developments of HDAC inhibitors: Emerging indications and novel molecules. Br J Clin Pharmacol 2021; 87:4577-4597. [PMID: 33971031 DOI: 10.1111/bcp.14889] [Citation(s) in RCA: 137] [Impact Index Per Article: 45.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 04/23/2021] [Accepted: 05/01/2021] [Indexed: 02/06/2023] Open
Abstract
The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a high number of clinical trials involving HDAC inhibitors, prompting us to further evaluate the current status of this class of therapeutic agents. In total, we have identified 32 agents with HDAC-inhibiting properties, of which 29 were found to interact with the HDAC enzymes as their primary therapeutic target. In this review, we provide an overview of the clinical drug development highlighting the recent advances and provide analysis of specific trials and, where applicable, chemical structures. We found haematologic neoplasms continue to represent the majority of clinical indications for this class of drugs; however, it is clear that there is an ongoing trend towards diversification. Therapies for non-oncology indications including HIV infection, muscular dystrophies, inflammatory diseases as well as neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia and Friedreich's ataxia are achieving promising clinical progress. Combinatory regimens are proving to be useful to improve responsiveness among FDA-approved agents; however, it often results in increased treatment-related toxicities. This analysis suggests that the indication field is broadening through a high number of clinical trials while several fields of preclinical development are also promising.
Collapse
Affiliation(s)
- Andrey D Bondarev
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.,Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
| | - Misty M Attwood
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
| | - Jörgen Jonsson
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
| | - Vladimir N Chubarev
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vadim V Tarasov
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.,Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Helgi B Schiöth
- Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden.,Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| |
Collapse
|
16
|
Ivanets NN, Svistunov AA, Chubarev VN, Kinkulkina MA, Tikhonova YG, Syzrantsev NS, Sologova SS, Ignatyeva NV, Mutig K, Tarasov VV. Can Molecular Biology Propose Reliable Biomarkers for Diagnosing Major Depression? Curr Pharm Des 2021; 27:305-318. [PMID: 33234092 DOI: 10.2174/1381612826666201124110437] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Accepted: 08/16/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Modern medicine has provided considerable knowledge of the pathophysiology of mental disorders at the body, systemic, organ and neurochemical levels of the biological organization of the body. Modern clinical diagnostics of depression have some problems, that is why psychiatric society makes use of diagnostics and taxonomy of different types of depression by implemention of modern molecular biomarkers in diagnostic procedures. But up to now, there are no reliable biomarkers of major depressive disorder (MDD) and other types of depression. OBJECTIVE The purpose of this review is to find fundamentals in pathological mechanisms of depression, which could be a basis for development of molecular and genetic biomarkers, being the most feasible for clinical use. METHOD This review summarizes the published data using PubMed, Science Direct, Google Scholar and Scopus. RESULTS In this review, we summarized and discussed findings in molecular biology, genetics, neuroplasticity, neurotransmitters, and neuroimaging that could increase our understanding of the biological foundations of depression and show new directions for the development of reliable biomarkers. We did not find any molecular and genetic biomarker approved for the clinic. But the Genome-Wide Association Study method promises some progress in the development of biomarkers based on SNP in the future. Epigenetic factors also are a promising target for biomarkers. We have found some differences in the etiology of different types of atypical and melancholic depression. This knowledge could be the basis for development of biomarkers for clinical practice in diagnosis, prognosis and selection of treatment. CONCLUSION Depression is not a monoetiological disease. Many pathological mechanisms are involved in depression, thus up to now, there is no approved and reliable biomarker for diagnosis, prognosis and correction of treatment of depression. The structural and functional complexity of the brain, the lack of invasive technology, poor correlations between genetic and clinical manifestation of depression, imperfect psychiatric classification and taxonomy of subtypes of disease are the main causes of this situation. One of the possible ways to come over this situation can be to pay attention to the trigger mechanism of disease and its subtypes. Researchers and clinicians should focus their efforts on searching the trigger mechanism of depression and different types of it . HPA axis can be a candidate for such trigger in depression caused by stress, because it influences the main branches of disease: neuroinflammation, activity of biogenic amines, oxidative and nitrosative stress, epigenetic factors, metabolomics, etc. But before we shall find any trigger mechanism, we need to create complex biomarkers reflecting genetic, epigenetic, metabolomics and other pathological changes in different types of depression. Recently the most encouraging results have been obtained from genetics and neuroimaging. Continuing research in these areas should be forced by using computational, statistical and systems biology approaches, which can allow to obtain more knowledge about the neurobiology of depression. In order to obtain clinically useful tests, search for biomarkers should use appropriate research methodologies with increasing samples and identifying more homogeneous groups of depressed patients.
Collapse
Affiliation(s)
- Nikolay N Ivanets
- Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russian Federation
| | - Andrey A Svistunov
- Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russian Federation
| | - Vladimir N Chubarev
- Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russian Federation
| | - Marina A Kinkulkina
- Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russian Federation
| | - Yuliya G Tikhonova
- Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russian Federation
| | - Nikita S Syzrantsev
- Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russian Federation
| | - Susanna S Sologova
- Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russian Federation
| | - Nelly V Ignatyeva
- Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russian Federation
| | - Kerim Mutig
- Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russian Federation
| | - Vadim V Tarasov
- Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russian Federation
| |
Collapse
|
17
|
Chubarev VN, Beeraka NM, Sinelnikov MY, Bulygin KV, Nikolenko VN, Mihaylenko E, Tarasov VV, Mikhaleva LM, Poltronieri P, Viswanadha VP, Somasundaram SG, Kirkland CE, Chen K, Liu J, Fan R, Kamal MA, Mironov AA, Madhunapantula SV, Pretorius E, Dindyaev SV, Muresanu C, Sukocheva OA. Health Science Community Will Miss This Bright and Uniting Star: In Memory of Professor Gjumrakch Aliev, M.D, Ph.D. Cancers (Basel) 2021; 13:cancers13081965. [PMID: 33921833 PMCID: PMC8072812 DOI: 10.3390/cancers13081965] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 04/15/2021] [Indexed: 02/05/2023] Open
Abstract
It is with deep sadness that we offer our memorial on the unexpected demise of our dear colleague, Professor Gjumrakch Aliev [...].
Collapse
Affiliation(s)
- Vladimir N. Chubarev
- Faculty of Pharmacology, Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, 119991 Moscow, Russia; (V.N.C.); (N.M.B.); (M.Y.S.); (K.V.B.); (V.N.N.); (E.M.); (V.V.T.)
| | - Narasimha M. Beeraka
- Faculty of Pharmacology, Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, 119991 Moscow, Russia; (V.N.C.); (N.M.B.); (M.Y.S.); (K.V.B.); (V.N.N.); (E.M.); (V.V.T.)
- Center of Excellence in Molecular Biology and Regenerative Medicine (CEMR), Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education and Research (JSS AHER), Bannimantapa, Sri Shivarathreeshwara Nagar, Mysuru, Karnataka 570 015, India;
| | - Mikhail Y. Sinelnikov
- Faculty of Pharmacology, Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, 119991 Moscow, Russia; (V.N.C.); (N.M.B.); (M.Y.S.); (K.V.B.); (V.N.N.); (E.M.); (V.V.T.)
| | - Kirill V. Bulygin
- Faculty of Pharmacology, Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, 119991 Moscow, Russia; (V.N.C.); (N.M.B.); (M.Y.S.); (K.V.B.); (V.N.N.); (E.M.); (V.V.T.)
- Faculty of Medicine, M.V. Lomonosov Moscow State University, 117192 Moscow, Russia
| | - Vladimir N. Nikolenko
- Faculty of Pharmacology, Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, 119991 Moscow, Russia; (V.N.C.); (N.M.B.); (M.Y.S.); (K.V.B.); (V.N.N.); (E.M.); (V.V.T.)
- Faculty of Medicine, M.V. Lomonosov Moscow State University, 117192 Moscow, Russia
| | - Elizaveta Mihaylenko
- Faculty of Pharmacology, Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, 119991 Moscow, Russia; (V.N.C.); (N.M.B.); (M.Y.S.); (K.V.B.); (V.N.N.); (E.M.); (V.V.T.)
| | - Vadim V. Tarasov
- Faculty of Pharmacology, Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, 119991 Moscow, Russia; (V.N.C.); (N.M.B.); (M.Y.S.); (K.V.B.); (V.N.N.); (E.M.); (V.V.T.)
| | | | - Palmiro Poltronieri
- Institute of Sciences of Food Productions, National Research Council of Italy, via Monteroni km 7, 73100 Lecce, Italy;
| | | | - Siva G. Somasundaram
- Department of Biological Sciences, Salem University, Salem, WV 26426, USA; (S.G.S.); (C.E.K.)
| | - Cecil E. Kirkland
- Department of Biological Sciences, Salem University, Salem, WV 26426, USA; (S.G.S.); (C.E.K.)
| | - Kuo Chen
- Cancer Center, Department of Radiation Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China; (K.C.); (J.L.); (R.F.)
| | - Junqi Liu
- Cancer Center, Department of Radiation Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China; (K.C.); (J.L.); (R.F.)
| | - Ruitai Fan
- Cancer Center, Department of Radiation Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China; (K.C.); (J.L.); (R.F.)
| | - Mohammad Amjad Kamal
- West China School of Nursing/Institutes for Systems Genetics, The Frontier Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China;
- King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia
- Enzymoics, 7 Peterlee Place, Novel Global Community Educational Foundation, Hebersham, NSW 2770, Australia
| | - Alexander A. Mironov
- Laboratory of Electron Microscopy, The FIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy;
| | - SubbaRao V. Madhunapantula
- Center of Excellence in Molecular Biology and Regenerative Medicine (CEMR), Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education and Research (JSS AHER), Bannimantapa, Sri Shivarathreeshwara Nagar, Mysuru, Karnataka 570 015, India;
| | - Etheresia Pretorius
- Department of Physiology, Faculty of Health Sciences, University of Pretoria, Arcadia 0007, South Africa;
| | - Sergey V. Dindyaev
- Department of Histology, Embryology & Cytology, Pediatric Faculty, Federal State Budgetary Educational Institution of Higher Education “Ivanovo State Medical Academy” of the Ministry of Healthcare of the Russian Federation (FSBEI HE IvSMA MOH Russia), 8 Sheremetyevsky Ave., 153012 Ivanovo, Russia;
| | - Cristian Muresanu
- Research Center for Applied Biotechnology in Diagnosis and Molecular Therapies, Str. Trifoiului nr. 12 G, 400478 Cluj-Napoca, Romania;
| | - Olga A. Sukocheva
- Discipline of Health Sciences, College of Nursing and Health Sciences, Flinders University of South Australia, Adelaide 5001, Australia
- Correspondence:
| |
Collapse
|
18
|
Affatato O, Moulin TC, Pisanu C, Babasieva VS, Russo M, Aydinlar EI, Torelli P, Chubarev VN, Tarasov VV, Schiöth HB, Mwinyi J. High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis. J Transl Med 2021; 19:133. [PMID: 33789668 PMCID: PMC8011097 DOI: 10.1186/s12967-021-02801-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Accepted: 03/19/2021] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Migraine and depression are highly prevalent and partly overlapping disorders that cause strong limitations in daily life. Patients tend to respond poorly to the therapies available for these diseases. OnabotulinumtoxinA has been proven to be an effective treatment for both migraine and depression. While many studies have addressed the effect of onabotulinumtoxinA in migraine or depression separately, a growing body of evidence suggests beneficial effects also for patients comorbid with migraine and depression. The current meta-analysis systematically investigates to what extent onabotulinumtoxinA is efficient in migraineurs with depression. METHODS A systematic literature search was performed based on PubMed, Scopus and Web of Science from the earliest date till October [Formula: see text], 2020. Mean, standard deviation (SD) and sample size have been used to evaluate improvement in depressive symptoms and migraine using random-effects empirical Bayes model. RESULTS Our search retrieved 259 studies, eight of which met the inclusion criteria. OnabotulinumtoxinA injections administered to patients with both chronic migraine and major depressive disorder led to mean reduction of [Formula: see text] points (CI [[Formula: see text]], [Formula: see text]) in the BDI scale, of [Formula: see text] points (CI [[Formula: see text]], [Formula: see text]) in the BDI-II scale and of [Formula: see text] points (CI [[Formula: see text]], [Formula: see text]) in the PHQ-9 scale, when evaluating depressive symptoms. In the case of the migraine-related symptoms, we found mean reductions of [Formula: see text] (CI [[Formula: see text]], [Formula: see text]) points in the HIT6 scale, [Formula: see text] (CI [[Formula: see text]], [Formula: see text]) in the MIDAS scale, [Formula: see text] (CI [[Formula: see text]], [Formula: see text]) points in the VAS scale and of [Formula: see text] (CI [[Formula: see text]], [Formula: see text]) migraine episodes per month. Comorbid patients showed slightly better improvements in BDI, HIT6 scores and migraine frequency compared to monomorbid patients. The latter group manifested better results in MIDAS and VAS scores. CONCLUSION Treatment with onabotulinumtoxinA leads to a significant reduction of disease severity of both chronic migraine and major depressive disorder in patients comorbid with both diseases. Comparative analyses suggest an equivalent strong effect in monomorbid and comorbid patients, with beneficial effects specifically seen for certain migraine features.
Collapse
Affiliation(s)
- Oreste Affatato
- Department of Neuroscience, University of Uppsala, Uppsala, Sweden.
| | - Thiago C Moulin
- Department of Neuroscience, University of Uppsala, Uppsala, Sweden
| | - Claudia Pisanu
- Department of Neuroscience, University of Uppsala, Uppsala, Sweden.,Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy
| | - Victoria S Babasieva
- Department of Neuroscience, University of Uppsala, Uppsala, Sweden.,Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Marco Russo
- Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy
| | - Elif I Aydinlar
- Department of Neurology, Acibadem University School of Medicine, Istanbul, Turkey
| | - Paola Torelli
- Headache Centre, Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Vladimir N Chubarev
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vadim V Tarasov
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.,Institute for Translational Medicine and Biothechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Helgi B Schiöth
- Department of Neuroscience, University of Uppsala, Uppsala, Sweden.,Institute for Translational Medicine and Biothechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Jessica Mwinyi
- Department of Neuroscience, University of Uppsala, Uppsala, Sweden
| |
Collapse
|
19
|
Markin PA, Brito A, Moskaleva NE, Tagliaro F, Tarasov VV, La Frano MR, Savitskii MV, Appolonova SA. Short- and medium-term exposures of diazepam induce metabolomic alterations associated with the serotonergic, dopaminergic, adrenergic and aspartic acid neurotransmitter systems in zebrafish (Danio rerio) embryos/larvae. Comp Biochem Physiol Part D Genomics Proteomics 2021; 38:100816. [PMID: 33610025 DOI: 10.1016/j.cbd.2021.100816] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 02/08/2021] [Accepted: 02/10/2021] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Diazepam is a well-known psychoactive drug widely used worldwide for the treatment of anxiety, seizures, alcohol withdrawal syndrome, muscle spasms, sleeplessness, agitation, and pre/post-operative sedation. It is part of the benzodiazepine family, substances known to primarily act by binding and enhancing gamma-aminobutyric acid (GABAA) receptors. The objective of the present work was to investigate the influence of short and medium-term diazepam exposures on neurotransmitters measured through targeted metabolomics using a zebrafish embryo model. METHODS Short-term (2.5 h) and medium-term (96 h) exposures to diazepam were performed at drug concentrations of 0.8, 1.6, 16, and 160 μg/L. Intervention groups were compared with a vehicle control group. Each group consisted of 20 zebrafish eggs/larvae. Metabolites related with neurotransmission were determined by ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS). RESULTS Thirty-six compounds were quantified. Significantly increased tryptophan and serotonin concentrations were found in the intervention groups receiving higher doses of diazepam in 2.5 h exposure (p < 0.05 control versus intervention groups). Tyrosine concentrations were higher (p < 0.05) at higher concentrations in 2.5 h exposure, but lower (p < 0.05) at higher concentrations in 96 h exposure. Both phenylalanine and aspartic acid concentrations were higher (p < 0.05) at higher doses in 2.5 h and 96 h exposure. CONCLUSIONS Short- and medium-term exposures to diazepam induce dose- and time-dependent metabolomic alterations associated with the serotonergic, dopaminergic/adrenergic, and aspartic acid neurotransmitter systems in zebrafish.
Collapse
Affiliation(s)
- Pavel A Markin
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; PhD Program in Nanosciences and Advanced Technologies, University of Verona, Verona, Italy; I.M. Sechenov First Moscow State Medical University, Russia
| | - Alex Brito
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Natalia E Moskaleva
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; World-Class Research Center "Digital Biodesign and Personalized Healthcare", I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Franco Tagliaro
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Unit of Forensic Medicine, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
| | | | - Michael R La Frano
- Department of Food Science and Nutrition, California Polytechnic State University, San Luis Obispo, CA, USA; Cal Poly Metabolomics Service Center, California Polytechnic State University, San Luis Obispo, CA, USA
| | - Mark V Savitskii
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; I.M. Sechenov First Moscow State Medical University, Russia
| | - Svetlana A Appolonova
- Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
| |
Collapse
|
20
|
Tarasov VV, Svistunov AA, Chubarev VN, Dostdar SA, Sokolov AV, Brzecka A, Sukocheva O, Neganova ME, Klochkov SG, Somasundaram SG, Kirkland CE, Aliev G. Extracellular vesicles in cancer nanomedicine. Semin Cancer Biol 2021; 69:212-225. [PMID: 31421263 DOI: 10.1016/j.semcancer.2019.08.017] [Citation(s) in RCA: 61] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 07/22/2019] [Accepted: 08/13/2019] [Indexed: 02/06/2023]
Abstract
To date, a lot of nanotechnological optitions are available for targeted drug delivery. Extracellular vesicles (EVs) are membrane structures that cells use for storage, transport, communication, and signaling. Recent research has focused on EVs as natural nanoparticles for drug delivery. This review sheds light on the application of EVs in cancer therapy, such as targeted chemotherapy, gene therapy, and vaccine development. Aspects of biogenesis, isolation, targeting, and loading of EVs are discussed in detail.
Collapse
Affiliation(s)
- Vadim V Tarasov
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia
| | - Andrey A Svistunov
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia
| | - Vladimir N Chubarev
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia
| | - Samira A Dostdar
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia
| | - Alexander V Sokolov
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia
| | - Anna Brzecka
- Department of Pulmonology and Lung Cancer, Wroclaw Medical University, Wroclaw, Poland
| | - Olga Sukocheva
- College of Nursing and Health Sciences, Flinders University, Bedford Park, South Australia, Australia
| | - Margarita E Neganova
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia
| | - Sergey G Klochkov
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia
| | | | - Cecil E Kirkland
- Department of Biological Sciences, Salem University, Salem, WV, USA
| | - Gjumrakch Aliev
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia; Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, USA.
| |
Collapse
|
21
|
Herrera AS, Solís Arias PE, Esparza MDCA, Bernal LFT, Bondarev AD, Fisenko VP, Chubarev VN, Minyaeva NN, Mikhaleva LM, Tarasov VV, Somasundaram SG, Kirkland CE, Aliev G. The Long-Term Effect of Medically Enhancing Melanin Intrinsic Bioenergetics Capacity in Prematurity. Curr Genomics 2020; 21:525-530. [PMID: 33214768 PMCID: PMC7604751 DOI: 10.2174/1389202921999200417172817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Revised: 08/09/2019] [Accepted: 03/16/2020] [Indexed: 11/22/2022] Open
Abstract
Background The ability of the human body to produce metabolic energy from light modifies fundamental concepts of biochemistry. Objective This review discusses the relationships between the long-accepted concept is that glucose has a unique dual role as an energy source and as the main source of carbon chains that are precursors of all organic matter. The capability of melanin to produce energy challenges this premise. Methods The prevalent biochemical concept, therefore, needs to be adjusted to incorporate a newly discovered state of Nature based on melanin's ability to dissociate water to produce energy and to re-form water from molecular hydrogen and oxygen. Results and Discussion Our findings regarding the potential implication of QIAPI-1 as a melanin precursor that has bioenergetics capabilities. Conclusion Specifically, we reported its promising application as a means for treating retinopathy of prematurity (ROP). The instant report focuses on the long-term treatment medical effects of melanin in treating ROP.
Collapse
Affiliation(s)
- Arturo S Herrera
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Paola E Solís Arias
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - María Del C A Esparza
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Luis F T Bernal
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Andrey D Bondarev
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Vladimir P Fisenko
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Vladimir N Chubarev
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Nina N Minyaeva
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Liudmila M Mikhaleva
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Vadim V Tarasov
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Siva G Somasundaram
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Cecil E Kirkland
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| | - Gjumrakch Aliev
- 1Human Photosynthesis Study Centre, Aguascalientes, Mexico; 2Universidad Autónoma de Aguascalientes, Aguascalientes, Ags., Mexico; 3Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico; 4I. M. Seche-nov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation; 5National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow101000, Russian Federation; 6Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow117418, Russian Federation; 7Department of Biological Sciences, Salem University, Salem, WV, USA; 8Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia; 9GALLY International Research Institute, San Antonio, TX- 78229, USA
| |
Collapse
|
22
|
Bure IV, Mikhaylenko DS, Kuznetsova EB, Alekseeva EA, Bondareva KI, Kalinkin AI, Lukashev AN, Tarasov VV, Zamyatnin AA, Nemtsova MV. Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment. J Pers Med 2020; 10:jpm10040205. [PMID: 33142700 PMCID: PMC7712090 DOI: 10.3390/jpm10040205] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 10/28/2020] [Accepted: 10/29/2020] [Indexed: 01/11/2023] Open
Abstract
Rheumatoid arthritis (RA) is the most common autoimmune disease worldwide. Epigenetic alternations of microRNAs (miRNAs) can contribute to its pathogenesis and progression. As the first line therapy with DMARDs is not always successful, other drugs and therapeutic targets should be applied. This study aims to measure the expression level of plasma miRNAs in RA patients treated with olokizumab and to evaluate their potential as prognostic biomarkers. The expression of 9 miRNAs was quantified in 103 RA patients before treatment and at weeks 12 and 24 of olokizumab therapy by reverse transcription-polymerase chain reaction (RT-PCR) assay and analyzed in groups of responders and non-responders. Almost all miRNAs changed their expression during therapy. The ROC curve analysis of the most prominent of them together with consequent univariate and multivariate regression analysis revealed statistically significant associations with the olokizumab therapy efficiency scores for miR-26b, miR-29, miR-451, and miR-522. Therefore, these miRNAs might be a potential therapeutic response biomarker.
Collapse
Affiliation(s)
- Irina V. Bure
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya str., 8-2, 119992 Moscow, Russia; (I.V.B.); (D.S.M.); (E.B.K.); (E.A.A.); (A.N.L.)
| | - Dmitry S. Mikhaylenko
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya str., 8-2, 119992 Moscow, Russia; (I.V.B.); (D.S.M.); (E.B.K.); (E.A.A.); (A.N.L.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechye str. 1, 115478 Moscow, Russia;
| | - Ekaterina B. Kuznetsova
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya str., 8-2, 119992 Moscow, Russia; (I.V.B.); (D.S.M.); (E.B.K.); (E.A.A.); (A.N.L.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechye str. 1, 115478 Moscow, Russia;
| | - Ekaterina A. Alekseeva
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya str., 8-2, 119992 Moscow, Russia; (I.V.B.); (D.S.M.); (E.B.K.); (E.A.A.); (A.N.L.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechye str. 1, 115478 Moscow, Russia;
| | - Kristina I. Bondareva
- Biostatistics Department, OCT Rus, Bolshaya Moskovskaya str., 8/2, 191002 Saint-Petersburg, Russia;
| | - Alexey I. Kalinkin
- Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechye str. 1, 115478 Moscow, Russia;
| | - Alexander N. Lukashev
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya str., 8-2, 119992 Moscow, Russia; (I.V.B.); (D.S.M.); (E.B.K.); (E.A.A.); (A.N.L.)
- Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia
| | - Vadim V. Tarasov
- Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University, 119991 Moscow, Russia;
| | - Andrey A. Zamyatnin
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya str., 8-2, 119992 Moscow, Russia; (I.V.B.); (D.S.M.); (E.B.K.); (E.A.A.); (A.N.L.)
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia
- Department of Biotechnology, Sirius University of Science and Technology, 1 Olympic Ave, 354340 Sochi, Russia
- Correspondence: (A.A.Z.J.); (M.V.N.)
| | - Marina V. Nemtsova
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya str., 8-2, 119992 Moscow, Russia; (I.V.B.); (D.S.M.); (E.B.K.); (E.A.A.); (A.N.L.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechye str. 1, 115478 Moscow, Russia;
- Correspondence: (A.A.Z.J.); (M.V.N.)
| |
Collapse
|
23
|
Muresanu C, Somasundaram SG, Neganova ME, Bovina EV, Vissarionov SV, Ofodile ONFC, Fisenko VP, Bragin V, Minyaeva NN, Chubarev VN, Klochkov SG, Tarasov VV, Mikhaleva LM, Kirkland CE, Aliev G. Updated Understanding of the Degenerative Disc Diseases - Causes Versus Effects - Treatments, Studies and Hypothesis. Curr Genomics 2020; 21:464-477. [PMID: 33093808 PMCID: PMC7536794 DOI: 10.2174/1389202921999200407082315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 08/20/2019] [Accepted: 03/16/2020] [Indexed: 01/22/2023] Open
Abstract
Background In this review we survey medical treatments and research strategies, and we discuss why they have failed to cure degenerative disc diseases or even slow down the degenerative process. Objective We seek to stimulate discussion with respect to changing the medical paradigm associated with treatments and research applied to degenerative disc diseases. Method Proposal We summarize a Biological Transformation therapy for curing chronic inflammations and degenerative disc diseases, as was previously described in the book Biological Transformations controlled by the Mind Volume 1. Preliminary Studies A single-patient case study is presented that documents complete recovery from an advanced lumbar bilateral discopathy and long-term hypertrophic chronic rhinitis by application of the method proposed. Conclusion Biological transformations controlled by the mind can be applied by men and women in order to improve their quality of life and cure degenerative disc diseases and chronic inflammations illnesses.
Collapse
Affiliation(s)
- Cristian Muresanu
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Siva G Somasundaram
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Margarita E Neganova
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Elena V Bovina
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Sergey V Vissarionov
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Okom N F C Ofodile
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Vladimir P Fisenko
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Valentin Bragin
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Nina N Minyaeva
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Vladimir N Chubarev
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Sergey G Klochkov
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Vadim V Tarasov
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Liudmila M Mikhaleva
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Cecil E Kirkland
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| | - Gjumrakch Aliev
- 1Romanian Television, TVR Cluj, 160 Donath Street, Cluj-Napoca, CJ 400293, Romania; 2Department of Biological Sciences, Salem University, Salem, WV, USA; 3Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russia; 4Department of Spinal Pathology and Neurosurgery, Turner Scientific and Research Institute for Children's Orthopedics, Street Parkovskya 64-68, Pushkin, Saint-Petersburg, 196603, Russia; 5Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charite, Universitaetsmedizin Berlin, AG: Theuring, Hessische Strasse 2-4, D-10115Berlin, Germany, 6Obie-Medical Corporate International LTD., Academic Section, 28 Oranye Street (American Quarters), Onitsha, Anambra State, Nigeria; 7I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russia; 8Stress Relief and Memory Training Center, 3101 Ocean Pkwy, Suite 1A, Brooklyn, NY, 11235, USA; 9National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia; 10Research Institute of Human Morphology, 3, Tsyurupy Str., Moscow, 117418, Russia; 11GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX78229, USA
| |
Collapse
|
24
|
Viswanadha VP, Dhivya V, Beeraka NM, Huang CY, Gavryushova LV, Minyaeva NN, Chubarev VN, Mikhaleva LM, Tarasov VV, Aliev G. The protective effect of piperine against isoproterenol-induced inflammation in experimental models of myocardial toxicity. Eur J Pharmacol 2020; 885:173524. [PMID: 32882215 DOI: 10.1016/j.ejphar.2020.173524] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 08/24/2020] [Accepted: 08/28/2020] [Indexed: 12/19/2022]
Abstract
Myocardial infarction (MI) eventually exacerbates inflammatory response due to the release of inflammatory and pro-inflammatory factors. The aim of this study is to explore the protective efficacy of piperine supplementation against the inflammatory response in isoproterenol (ISO)-induced MI. Masson Trichome staining was executed to determine myocardial tissue architecture. Immunohistochemistry was performed for IL-6, TNF-α. RT-PCR studies were performed to ascertain the gene expression of IL-6, TNF-α, iNOS, eNOS, MMP-2, MMP-9, and collagen-III. Western blotting was performed to determine expression of HIF-1α, VEGF, Nrf-2, NF-ƙB, Cox-2, p-38, phospho-p38, ERK-1/2, phospho-ERK-1/2, and collagen-I. HIF-1α, VEGF, and iNOS expression were significantly upregulated with concomitant decline in eNOS expression in the heart myocardial tissue of rats received ISO alone whereas piperine pretreatment prevented these changes in ISO administered rats. Current results revealed ROS-mediated activation of MAPKs, namely, p-p38, p-ERK1/2 in the heart tissue of ISO administered group. Piperine pretreatment significantly prevented these changes in ISO treated group. NF-κB is involved in the modulation of gene expressions responsible for tissue repair. ISO-induced NF-κB-p65 expression was significantly reduced in the group pretreated with piperine and mitigated extent of myocardial inflammation. A significant increase in cardiac fibrosis upon ISO treatment was reported due to the increased hydroxyproline content, MMP-2 & 9 and upregulation of collagen-I protein compared to control group. All these cardiac hypertrophy markers were decreased in 'piperine pretreated ISO administered group' compared to group received ISO injection. Current findings concluded that piperine as a nutritional intervention could prevent inflammation of myocardium in ISO-induced MI.
Collapse
Affiliation(s)
- Vijaya Padma Viswanadha
- Translational Research Laboratory, Department of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu, India; China Medical University, Lifu Teaching Building 12F, 91 Hsueh-Shih Road, Taichung, 40402, Taiwan.
| | - Velumani Dhivya
- Translational Research Laboratory, Department of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu, India
| | - Narasimha Murthy Beeraka
- Translational Research Laboratory, Department of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu, India
| | - Chih-Yang Huang
- China Medical University, Lifu Teaching Building 12F, 91 Hsueh-Shih Road, Taichung, 40402, Taiwan
| | - Liliya V Gavryushova
- Department of Therapeutic Dentistry, Saratov State Medical University named after V.I. Razumovsky, 410012, Saratov, Russia
| | - Nina N Minyaeva
- National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russia
| | - Vladimir N Chubarev
- Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia
| | - Liudmila M Mikhaleva
- Research Institute of Human Morphology, Russian Academy of Medical Science, Street Tsyurupa 3, Moscow, 117418, Russia
| | - Vadim V Tarasov
- Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia
| | - Gjumrakch Aliev
- Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, Moscow, 119991, Russia; Research Institute of Human Morphology, Russian Academy of Medical Science, Street Tsyurupa 3, Moscow, 117418, Russia; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow Region, 142432, Russia; GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, USA.
| |
Collapse
|
25
|
Brzecka A, Sarul K, Dyła T, Avila-Rodriguez M, Cabezas-Perez R, Chubarev VN, Minyaeva NN, Klochkov SG, Neganova ME, Mikhaleva LM, Somasundaram SG, Kirkland CE, Tarasov VV, Aliev G. The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer. Curr Genomics 2020; 21:444-453. [PMID: 33093806 PMCID: PMC7536792 DOI: 10.2174/1389202921999200403151720] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2019] [Revised: 07/31/2019] [Accepted: 03/16/2020] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Sleep disorders have emerged as potential cancer risk factors. OBJECTIVE This review discusses the relationships between sleep, obesity, and breathing disorders with concomitant risks of developing cancer. RESULTS Sleep disorders result in abnormal expression of clock genes, decreased immunity, and melatonin release disruption. Therefore, these disorders may contribute to cancer development. Moreover, in sleep breathing disorder, which is frequently experienced by obese persons, the sufferer experiences intermittent hypoxia that may stimulate cancer cell proliferation. DISCUSSION During short- or long- duration sleep, sleep-wake rhythm disruption may occur. Insomnia and obstructive sleep apnea increase cancer risks. In short sleepers, an increased risk of stomach cancer, esophageal squamous cell cancer, and breast cancer was observed. Among long sleepers (>9 hours), the risk of some hematologic malignancies is elevated. CONCLUSION Several factors including insomnia, circadian disruption, obesity, and intermittent hypoxia in obstructive sleep apnea are contributing risk factors for increased risk of several types of cancers. However, further studies are needed to determine the more significant of these risk factors and their interactions.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Gjumrakch Aliev
- Address correspondence to this author at the GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, USA; Tel: +1(440) 263-7461; +7-964-493-1515; E-mails: and
| |
Collapse
|
26
|
Mikhaylenko DS, Nemtsova MV, Bure IV, Kuznetsova EB, Alekseeva EA, Tarasov VV, Lukashev AN, Beloukhova MI, Deviatkin AA, Zamyatnin AA. Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response. Int J Mol Sci 2020; 21:E4911. [PMID: 32664585 PMCID: PMC7402327 DOI: 10.3390/ijms21144911] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Revised: 07/08/2020] [Accepted: 07/09/2020] [Indexed: 12/11/2022] Open
Abstract
Rheumatoid arthritis (RA) is the most common inflammatory arthropathy worldwide. Possible manifestations of RA can be represented by a wide variability of symptoms, clinical forms, and course options. This multifactorial disease is triggered by a genetic predisposition and environmental factors. Both clinical and genealogical studies have demonstrated disease case accumulation in families. Revealing the impact of candidate gene missense variants on the disease course elucidates understanding of RA molecular pathogenesis. A multivariate genomewide association study (GWAS) based analysis identified the genes and signalling pathways involved in the pathogenesis of the disease. However, these identified RA candidate gene variants only explain 30% of familial disease cases. The genetic causes for a significant proportion of familial RA have not been determined until now. Therefore, it is important to identify RA risk groups in different populations, as well as the possible prognostic value of some genetic variants for disease development, progression, and treatment. Our review has two purposes. First, to summarise the data on RA candidate genes and the increased disease risk associated with these alleles in various populations. Second, to describe how the genetic variants can be used in the selection of drugs for the treatment of RA.
Collapse
Affiliation(s)
- Dmitry S. Mikhaylenko
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (M.V.N.); (I.V.B.); (E.B.K.); (E.A.A.); (A.N.L.); (M.I.B.); (A.A.D.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, 115478 Moscow, Russia
| | - Marina V. Nemtsova
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (M.V.N.); (I.V.B.); (E.B.K.); (E.A.A.); (A.N.L.); (M.I.B.); (A.A.D.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, 115478 Moscow, Russia
| | - Irina V. Bure
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (M.V.N.); (I.V.B.); (E.B.K.); (E.A.A.); (A.N.L.); (M.I.B.); (A.A.D.)
| | - Ekaterina B. Kuznetsova
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (M.V.N.); (I.V.B.); (E.B.K.); (E.A.A.); (A.N.L.); (M.I.B.); (A.A.D.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, 115478 Moscow, Russia
| | - Ekaterina A. Alekseeva
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (M.V.N.); (I.V.B.); (E.B.K.); (E.A.A.); (A.N.L.); (M.I.B.); (A.A.D.)
- Laboratory of Epigenetics, Research Centre for Medical Genetics, 115478 Moscow, Russia
| | - Vadim V. Tarasov
- Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University, 119991 Moscow, Russia;
| | - Alexander N. Lukashev
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (M.V.N.); (I.V.B.); (E.B.K.); (E.A.A.); (A.N.L.); (M.I.B.); (A.A.D.)
- Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia
| | - Marina I. Beloukhova
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (M.V.N.); (I.V.B.); (E.B.K.); (E.A.A.); (A.N.L.); (M.I.B.); (A.A.D.)
| | - Andrei A. Deviatkin
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (M.V.N.); (I.V.B.); (E.B.K.); (E.A.A.); (A.N.L.); (M.I.B.); (A.A.D.)
| | - Andrey A. Zamyatnin
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; (M.V.N.); (I.V.B.); (E.B.K.); (E.A.A.); (A.N.L.); (M.I.B.); (A.A.D.)
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia
| |
Collapse
|
27
|
Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schiöth HB. Opportunities and challenges for drug discovery in modulating Adhesion G protein-coupled receptor (GPCR) functions. Expert Opin Drug Discov 2020; 15:1291-1307. [DOI: 10.1080/17460441.2020.1791075] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Andrey D. Bondarev
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
- Department Of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
| | - Misty M. Attwood
- Department Of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
| | - Jörgen Jonsson
- Department Of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
| | - Vladimir N. Chubarev
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vadim V. Tarasov
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
- Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Helgi B. Schiöth
- Department Of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
- Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| |
Collapse
|
28
|
Larin I, Zhang Y, Gasparian A, Gan L, Miskimen R, Khandaker M, Dale D, Danagoulian S, Pasyuk E, Gao H, Ahmidouch A, Ambrozewicz P, Baturin V, Burkert V, Clinton E, Deur A, Dolgolenko A, Dutta D, Fedotov G, Feng J, Gevorkyan S, Glamazdin A, Guo L, Isupov E, Ito MM, Klein F, Kowalski S, Kubarovsky A, Kubarovsky V, Lawrence D, Lu H, Ma L, Matveev V, Morrison B, Micherdzinska A, Nakagawa I, Park K, Pedroni R, Phelps W, Protopopescu D, Rimal D, Romanov D, Salgado C, Shahinyan A, Sober D, Stepanyan S, Tarasov VV, Taylor S, Vasiliev A, Wood M, Ye L, Zihlmann B. Precision measurement of the neutral pion lifetime. Science 2020; 368:506-509. [PMID: 32355026 DOI: 10.1126/science.aay6641] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Accepted: 03/30/2020] [Indexed: 11/02/2022]
Abstract
The explicit breaking of the axial symmetry by quantum fluctuations gives rise to the so-called axial anomaly. This phenomenon is solely responsible for the decay of the neutral pion π0 into two photons (γγ), leading to its unusually short lifetime. We precisely measured the decay width Γ of the [Formula: see text] process. The differential cross sections for π0 photoproduction at forward angles were measured on two targets, carbon-12 and silicon-28, yielding [Formula: see text], where stat. denotes the statistical uncertainty and syst. the systematic uncertainty. We combined the results of this and an earlier experiment to generate a weighted average of [Formula: see text] Our final result has a total uncertainty of 1.50% and confirms the prediction based on the chiral anomaly in quantum chromodynamics.
Collapse
Affiliation(s)
- I Larin
- Alikhanov Institute for Theoretical and Experimental Physics, National Research Center (NRC) "Kurchatov Institute," Moscow, 117218, Russia.,Department of Physics, University of Massachusetts, Amherst, MA 01003, USA
| | - Y Zhang
- Department of Physics, Duke University, Durham, NC 27708, USA.,Triangle Universities Nuclear Laboratory, Durham, NC 27708, USA
| | - A Gasparian
- Department of Physics, North Carolina A&T State University, Greensboro, NC 27411, USA.
| | - L Gan
- Department of Physics and Physical Oceanography, University of North Carolina Wilmington, Wilmington, NC 28403, USA
| | - R Miskimen
- Department of Physics, University of Massachusetts, Amherst, MA 01003, USA
| | - M Khandaker
- Department of Physics, Norfolk State University, Norfolk, VA 23504, USA
| | - D Dale
- Department of Physics and Nuclear Engineering, Idaho State University, Pocatello, ID 83209, USA
| | - S Danagoulian
- Department of Physics, North Carolina A&T State University, Greensboro, NC 27411, USA
| | - E Pasyuk
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - H Gao
- Department of Physics, Duke University, Durham, NC 27708, USA.,Triangle Universities Nuclear Laboratory, Durham, NC 27708, USA
| | - A Ahmidouch
- Department of Physics, North Carolina A&T State University, Greensboro, NC 27411, USA
| | - P Ambrozewicz
- Department of Physics, North Carolina A&T State University, Greensboro, NC 27411, USA
| | - V Baturin
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - V Burkert
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - E Clinton
- Department of Physics, University of Massachusetts, Amherst, MA 01003, USA
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - A Dolgolenko
- Alikhanov Institute for Theoretical and Experimental Physics, National Research Center (NRC) "Kurchatov Institute," Moscow, 117218, Russia
| | - D Dutta
- Department of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, USA
| | - G Fedotov
- Department of Physics, Moscow State University, Moscow 119991, Russia.,B. P. Konstantinov Petersburg Nuclear Physics Institute, NRC "Kurchatov Institute," Gatchina, St. Petersburg, 188300, Russia
| | - J Feng
- Department of Physics and Physical Oceanography, University of North Carolina Wilmington, Wilmington, NC 28403, USA
| | - S Gevorkyan
- Joint Institute for Nuclear Research, Dubna, 141980, Russia
| | - A Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov, 310108, Ukraine
| | - L Guo
- Department of Physics, Florida International University, Miami, FL 33199, USA
| | - E Isupov
- Department of Physics, Moscow State University, Moscow 119991, Russia
| | - M M Ito
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - F Klein
- Department of Physics, The Catholic University of America, Washington, DC 20064, USA
| | - S Kowalski
- Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - A Kubarovsky
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - V Kubarovsky
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - D Lawrence
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - H Lu
- Department of Physics, Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - L Ma
- School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000, China
| | - V Matveev
- Alikhanov Institute for Theoretical and Experimental Physics, National Research Center (NRC) "Kurchatov Institute," Moscow, 117218, Russia
| | - B Morrison
- Department of Physics, Arizona State University, Tempe, AZ 85281, USA
| | - A Micherdzinska
- Department of Physics, George Washington University, Washington, DC 20064, USA
| | - I Nakagawa
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - K Park
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - R Pedroni
- Department of Physics, North Carolina A&T State University, Greensboro, NC 27411, USA
| | - W Phelps
- Department of Physics, Computer Science and Engineering, Christopher Newport University, Newport News, VA 23606, USA
| | - D Protopopescu
- School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, UK
| | - D Rimal
- Department of Physics, Florida International University, Miami, FL 33199, USA
| | - D Romanov
- Department of Physics, Moscow Engineering Physics Institute, Moscow, Russia
| | - C Salgado
- Department of Physics, Norfolk State University, Norfolk, VA 23504, USA
| | - A Shahinyan
- Yerevan Physics Institute, Yerevan 0036, Armenia
| | - D Sober
- Department of Physics, The Catholic University of America, Washington, DC 20064, USA
| | - S Stepanyan
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - V V Tarasov
- Alikhanov Institute for Theoretical and Experimental Physics, National Research Center (NRC) "Kurchatov Institute," Moscow, 117218, Russia
| | - S Taylor
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | - A Vasiliev
- Institute for High Energy Physics, NRC "Kurchatov Institute," Protvino, 142281, Russia
| | - M Wood
- Department of Physics, University of Massachusetts, Amherst, MA 01003, USA
| | - L Ye
- Department of Physics and Astronomy, Mississippi State University, Mississippi State, MS 39762, USA
| | - B Zihlmann
- Thomas Jefferson National Accelerator Facility, Newport News, VA 23606, USA
| | | |
Collapse
|
29
|
Kirichenko TV, Sukhorukov VN, Markin AM, Nikiforov NG, Liu PY, Sobenin IA, Tarasov VV, Orekhov AN, Aliev G. Medicinal Plants as a Potential and Successful Treatment Option in the Context of Atherosclerosis. Front Pharmacol 2020; 11:403. [PMID: 32322201 PMCID: PMC7156611 DOI: 10.3389/fphar.2020.00403] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Accepted: 03/17/2020] [Indexed: 12/22/2022] Open
Abstract
Atherosclerosis is a chronic multifactorial disease characterized by mainly changes of blood lipids profile and inflammation in vessel wall. The cardiovascular disease based on atherosclerosis is currently the leading cause of mortality in developed countries. Therefore, timely prevention and therapy of atherosclerosis are able to reduce the risk of the development of its clinical manifestations. Anti-atherosclerotic activity of medicinal plants mainly appears in their multiple effects such as anti-inflammatory, antioxidant, anti-atherogenic, hypotensive, lipid-lowering, anti-thrombotic. Moreover, most of medicinal plants are characterized by their pleiotropic anti-atherosclerotic action. In addition, the medicinal plants-derived pharmacological substances and/or compounds are characterized by relative safety and fewer side effects that allows considering them as one of potential anti-atherosclerotic effective agents. The direct anti-atherosclerotic effect of some medicinal plants was confirmed in clinical trials of carotid Intima-media thickness (IMT) progression during long-term medication with medicinal plants. This review attempted to determine the current status of the databases PubMed and Scopus (until November, 2019) to investigate the medicinal plants possessing anti-atherosclerotic activity in experimental and clinical studies.
Collapse
Affiliation(s)
- Tatiana V. Kirichenko
- Laboratory of Infection Pathology and Molecular Microecology, Research Institute of Human Morphology, Moscow, Russia
- Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russia
- Laboratory of Medical Genetics, National Medical Research Center of Cardiology, Moscow, Russia
| | - Vasily N. Sukhorukov
- Laboratory of Infection Pathology and Molecular Microecology, Research Institute of Human Morphology, Moscow, Russia
- Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russia
- Laboratory of Medical Genetics, National Medical Research Center of Cardiology, Moscow, Russia
| | - Alexander M. Markin
- Laboratory of Infection Pathology and Molecular Microecology, Research Institute of Human Morphology, Moscow, Russia
| | - Nikita G. Nikiforov
- Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russia
- Laboratory of Medical Genetics, National Medical Research Center of Cardiology, Moscow, Russia
| | - Ping-Yen Liu
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- Division of Cardiology, College of Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
| | - Igor A. Sobenin
- Laboratory of Infection Pathology and Molecular Microecology, Research Institute of Human Morphology, Moscow, Russia
- Laboratory of Medical Genetics, National Medical Research Center of Cardiology, Moscow, Russia
| | - Vadim V. Tarasov
- Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Alexander N. Orekhov
- Laboratory of Infection Pathology and Molecular Microecology, Research Institute of Human Morphology, Moscow, Russia
- Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russia
| | - Gjumrakch Aliev
- Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Russia
- GALLY International Research Institute, San Antonio, TX, United States
- Laboratory of Molecular Pathology, Research Institute of Human Morphology, Moscow, Russia
| |
Collapse
|
30
|
Sukocheva OA, Furuya H, Ng ML, Friedemann M, Menschikowski M, Tarasov VV, Chubarev VN, Klochkov SG, Neganova ME, Mangoni AA, Aliev G, Bishayee A. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacol Ther 2020; 207:107464. [PMID: 31863815 DOI: 10.1016/j.pharmthera.2019.107464] [Citation(s) in RCA: 64] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Accepted: 12/10/2019] [Indexed: 02/07/2023]
Abstract
Inflammatory gastrointestinal (GI) diseases and malignancies are associated with growing morbidity and cancer-related mortality worldwide. GI tumor and inflammatory cells contain activated sphingolipid-metabolizing enzymes, including sphingosine kinase 1 (SphK1) and SphK2, that generate sphingosine-1-phosphate (S1P), a highly bioactive compound. Many inflammatory responses, including lymphocyte trafficking, are directed by circulatory S1P, present in high concentrations in both the plasma and the lymph of cancer patients. High fat and sugar diet, disbalanced intestinal flora, and obesity have recently been linked to activation of inflammation and SphK/S1P/S1P receptor (S1PR) signaling in various GI pathologies, including cancer. SphK1 overexpression and activation facilitate and enhance the development and progression of esophageal, gastric, and colon cancers. SphK/S1P axis, a mediator of inflammation in the tumor microenvironment, has recently been defined as a target for the treatment of GI disease states, including inflammatory bowel disease and colitis. Several SphK1 inhibitors and S1PR antagonists have been developed as novel anti-inflammatory and anticancer agents. In this review, we analyze the mechanisms of SphK/S1P signaling in GI tissues and critically appraise recent studies on the role of SphK/S1P/S1PR in inflammatory GI disorders and cancers. The potential role of SphK/S1PR inhibitors in the prevention and treatment of inflammation-mediated GI diseases, including GI cancer, is also evaluated.
Collapse
Affiliation(s)
- Olga A Sukocheva
- Discipline of Health Sciences, College of Nursing and Health Sciences, Flinders University, Bedford Park, South Australia 5042, Australia
| | - Hideki Furuya
- Department of Surgery, Samuel Oschin Cancer Center Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Mei Li Ng
- Advanced Medical and Dental Institute, University Sains 13200 Kepala Batas, Pulau Pinang, Malaysia
| | - Markus Friedemann
- Institute of Clinical Chemistry and Laboratory Medicine, University Hospital `Carl Gustav Carus`, Technical University of Dresden, Dresden 01307, Germany
| | - Mario Menschikowski
- Institute of Clinical Chemistry and Laboratory Medicine, University Hospital `Carl Gustav Carus`, Technical University of Dresden, Dresden 01307, Germany
| | - Vadim V Tarasov
- Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia
| | - Vladimir N Chubarev
- Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia
| | - Sergey G Klochkov
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka 142432, Russia
| | - Margarita E Neganova
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka 142432, Russia
| | - Arduino A Mangoni
- Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Centre, Bedford Park, South Australia 5042, Australia
| | - Gjumrakch Aliev
- Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka 142432, Russia; GALLY International Research Institute, San Antonio, TX 78229, USA; Research Institute of Human Morphology, Moscow 117418, Russia
| | - Anupam Bishayee
- Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA.
| |
Collapse
|
31
|
Tarasov VV, Svistunov AA, Chubarev VN, Zatsepilova TA, Preferanskaya NG, Stepanova OI, Sokolov AV, Dostdar SA, Minyaeva NN, Neganova ME, Klochkov SG, Mikhaleva LM, Somasundaram SG, Kirkland CE, Aliev G. Feasibility of Targeting Glioblastoma Stem Cells: From Concept to Clinical Trials. Curr Top Med Chem 2020; 19:2974-2984. [PMID: 31721715 DOI: 10.2174/1568026619666191112140939] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2019] [Revised: 08/25/2019] [Accepted: 09/06/2019] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Glioblastoma is a highly aggressive and invasive brain and Central Nervous System (CNS) tumor. Current treatment options do not prolong overall survival significantly because the disease is highly prone to relapse. Therefore, research to find new therapies is of paramount importance. It has been discovered that glioblastomas contain a population of cells with stem-like properties and that these cells are may be responsible for tumor recurrence. METHODS A review of relevant papers and clinical trials in the field was conducted. A PubMed search with related keywords was used to gather the data. For example, "glioblastoma stem cells AND WNT signaling" is an example used to find information on clinical trials using the database ClinicalTrials.gov. RESULTS Cancer stem cell research has several fundamental issues and uncertainties that should be taken into consideration. Theoretically, a number of treatment options that target glioblastoma stem cells are available for patients. However, only a few of them have obtained promising results in clinical trials. Several strategies are still under investigation. CONCLUSION The majority of treatments to target cancer stem cells have failed during clinical trials. Taking into account a number of biases in the field and the number of unsuccessful investigations, the application of the cancer stem cells concept is questionable in clinical settings, at least with respect to glioblastoma.
Collapse
Affiliation(s)
- Vadim V Tarasov
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991,Russian Federation
| | - Andrey A Svistunov
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991,Russian Federation
| | - Vladimir N Chubarev
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991,Russian Federation
| | - Tamara A Zatsepilova
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991,Russian Federation
| | - Nina G Preferanskaya
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991,Russian Federation
| | - Olga I Stepanova
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991,Russian Federation
| | - Alexander V Sokolov
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991,Russian Federation
| | - Samira A Dostdar
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991,Russian Federation
| | - Nina N Minyaeva
- National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow 101000,Russian Federation
| | - Margarita E Neganova
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432,Russian Federation
| | - Sergey G Klochkov
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432,Russian Federation
| | - Liudmila M Mikhaleva
- Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow 117418,Russian Federation
| | - Siva G Somasundaram
- Department of Biological Sciences, Salem University, Salem, WV,United States
| | - Cecil E Kirkland
- Department of Biological Sciences, Salem University, Salem, WV,United States
| | - Gjumrakch Aliev
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991,Russian Federation.,Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432,Russian Federation.,Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow 117418,Russian Federation.,GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX 78229,United States
| |
Collapse
|
32
|
Tarasov VV, Svistunov AA, Chubarev VN, Sologova SS, Mukhortova P, Levushkin D, Somasundaram SG, Kirkland CE, Bachurin SO, Aliev G. Alterations of Astrocytes in the Context of Schizophrenic Dementia. Front Pharmacol 2020; 10:1612. [PMID: 32116664 PMCID: PMC7020441 DOI: 10.3389/fphar.2019.01612] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Accepted: 12/10/2019] [Indexed: 12/19/2022] Open
Abstract
The levels of the astrocyte markers (GFAP, S100B) were increased unevenly in patients with schizophrenia. Reactive astrogliosis was found in approximately 70% of patients with schizophrenia. The astrocytes play a major role in etiology and pathogenesis of schizophrenia. Astrocytes produce the components that altered in schizophrenia extracellular matrix system which are involved in inflammation, functioning of interneurons, glio-, and neurotransmitter system, especially glutamate system. Astrocytes activate the interneurons through glutamate release and ATP. Decreased expression of astrocyte glutamate transporters was observed in patients with schizophrenia. Astrocytes influence on N-methyl-d-aspartate (NMDA) receptors via D-serine, an agonist of the glycine-binding site of NMDA receptors, and kynurenic acid, an endogenous antagonist. NMDA receptors, on its turn, control the impulses of dopamine neurons. Therefore following theories of schizophrenia are proposed. They are a) activation of astrocytes for neuroinflammation, b) glutamate and dopamine theory, as astrocyte products control the activity of NMDA receptors, which influence on the dopamine neurons.
Collapse
Affiliation(s)
- Vadim V Tarasov
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Andrey A Svistunov
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Vladimir N Chubarev
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Susanna S Sologova
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Polina Mukhortova
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Dmitrii Levushkin
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Siva G Somasundaram
- Department of Biological Sciences, Salem University, Salem, WV, United States
| | - Cecil E Kirkland
- Department of Biological Sciences, Salem University, Salem, WV, United States
| | - Sergey O Bachurin
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, Russia
| | - Gjumrakch Aliev
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.,Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, Russia.,Federal State Budgetary Institution, Research Institute of Human Morphology, Russian Federation, Moscow, Russia.,GALLY International Research Institute, San Antonio, TX, United States
| |
Collapse
|
33
|
Deviatkin AA, Vakulenko YA, Akhmadishina LV, Tarasov VV, Beloukhova MI, Zamyatnin Jr. AA, Lukashev AN. Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy. Biomedicines 2020; 8:biomedicines8010009. [PMID: 31936504 PMCID: PMC7168286 DOI: 10.3390/biomedicines8010009] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 01/03/2020] [Accepted: 01/07/2020] [Indexed: 02/07/2023] Open
Abstract
Rheumatoid arthritis (RA) is a systemic inflammatory joint disease affecting about 1% of the population worldwide. Current treatment approaches do not ensure a cure for every patient. Moreover, classical regimens are based on nontargeted systemic immune suppression and have significant side effects. Biological treatment has advanced considerably but efficacy and specificity issues remain. Gene therapy is one of the potential future directions for RA therapy, which is rapidly developing. Several gene therapy trials done so far have been of moderate success, but experimental and genetics studies have yielded novel targets. As a result, the arsenal of gene therapy tools keeps growing. Currently, both viral and nonviral delivery systems are used for RA therapy. Herein, we review recent approaches for RA gene therapy.
Collapse
Affiliation(s)
- Andrei A. Deviatkin
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia; (M.I.B.); (A.A.Z.J.); (A.N.L.)
- Correspondence:
| | - Yulia A. Vakulenko
- Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia; (Y.A.V.); (L.V.A.)
- Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia
| | - Ludmila V. Akhmadishina
- Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia; (Y.A.V.); (L.V.A.)
| | - Vadim V. Tarasov
- Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University, 119991 Moscow, Russia;
| | - Marina I. Beloukhova
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia; (M.I.B.); (A.A.Z.J.); (A.N.L.)
| | - Andrey A. Zamyatnin Jr.
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia; (M.I.B.); (A.A.Z.J.); (A.N.L.)
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia
| | - Alexander N. Lukashev
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia; (M.I.B.); (A.A.Z.J.); (A.N.L.)
- Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia; (Y.A.V.); (L.V.A.)
| |
Collapse
|
34
|
Rayavarapu S, Yarla NS, Kadiri SK, Bishayee A, Vidavalur S, Tadikonda R, Basha M, Pidugu VR, Dowluru KSVGK, Lakappa DB, Kamal MA, Ashraf GM, Tarasov VV, Chubarev VN, Klochkov SG, Barreto GE, Bachurin SO, Aliev G. Publisher Correction: Synthesis of Saccharumoside-B analogue with potential of antiproliferative and pro-apoptotic activities. Sci Rep 2020; 10:185. [PMID: 31913323 PMCID: PMC6949224 DOI: 10.1038/s41598-019-57392-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- Srinuvasarao Rayavarapu
- Department of Organic Chemistry, Foods, Drugs and Water, College of Science and Technology, Andhra University, Visakhapatnam, 530 003, Andhra Pradesh, India
| | - Nagendra Sastry Yarla
- Department of Biochemistry and Bioinformatics, School of Life Sciences, Institute of Science, GITAM University, Visakhapatnam, 530 045, Andhra Pradesh, India.,Department of Animal Biology, University of Hyderabad, Hyderabad, 500 046, Telangana, India
| | - Sunanda Kumari Kadiri
- Department of Microbiology, College of Science and Technology, Andhra University, Visakhapatnam, 530 003, Andhra Pradesh, India
| | - Anupam Bishayee
- Department of Pharmaceutical Sciences, College of Pharmacy, Larkin Health Sciences Institute, Miami, FL, 33169, USA
| | - Siddaiah Vidavalur
- Department of Organic Chemistry, Foods, Drugs and Water, College of Science and Technology, Andhra University, Visakhapatnam, 530 003, Andhra Pradesh, India
| | - Ramu Tadikonda
- Department of Organic Chemistry, Foods, Drugs and Water, College of Science and Technology, Andhra University, Visakhapatnam, 530 003, Andhra Pradesh, India
| | - Mahaboob Basha
- Department of Organic Chemistry, Foods, Drugs and Water, College of Science and Technology, Andhra University, Visakhapatnam, 530 003, Andhra Pradesh, India
| | - Vijaya Rao Pidugu
- Excelra Knowledge Solutions Private Limited, NSL SEZ ARENA, IDA Uppal, Hyderabad, 500 039, Telangana, India
| | - Kaladhar S V G K Dowluru
- Department of Microbiology and Bioinformatics, Bilaspur University, Bilaspur, 495 001, Chhattisgarh, India
| | - Dhananjaya Bhadrapura Lakappa
- Toxinology/Toxicology and Drug Discovery Unit, Center for Emerging Technologies, Jain Global Campus, Jain University, Kanakapura Taluk, Ramanagara, 562 112, Karnataka, India
| | - Mohammad A Kamal
- Enzymoics and Novel Global Community Educational Foundation, Hebersham, NSW, Australia.,King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Ghulam Md Ashraf
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Vadim V Tarasov
- Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russia
| | - Vladimir N Chubarev
- Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russia
| | - Sergey G Klochkov
- Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Severniy Proezd, Chernogolovka, Moscow Region, 1142432, Russia
| | - George E Barreto
- Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, D. C., Colombia.,Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile
| | - Sergey O Bachurin
- Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Severniy Proezd, Chernogolovka, Moscow Region, 1142432, Russia
| | - Gjumrakch Aliev
- Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Severniy Proezd, Chernogolovka, Moscow Region, 1142432, Russia. .,"GALLY" International Biomedical Research Consulting LLC, San Antonio, TX, 78229, USA. .,School of Health Sciences and Healthcare Administration, University of Atlanta, Johns Creek, GA, 30097, USA.
| |
Collapse
|
35
|
Vissarionov SV, Kokushin DN, Khusainov NO, Kartavenko KA, Avila-Rodriguez MF, Somasundaram SG, Kirkland CE, Tarasov VV, Aliev G. Comparing the Treatment of Congenital Spine Deformity Using Freehand Techniques In Vivo and 3D-Printed Templates In Vitro (Prospective-Retrospective Single-Center Analytical Single-Cohort Study). Adv Ther 2020; 37:402-419. [PMID: 31755038 DOI: 10.1007/s12325-019-01152-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Indexed: 10/25/2022]
Abstract
INTRODUCTION Hemivertebrae excision with local posterior instrumentation is the most common technique for treatment of patients with congenital spine deformity-it is performed at a very young age. We conducted a comparative analysis for accuracy of pedicle screw positioning in infants with congenital scoliosis of the thoracolumbar area inserted using freehand technique in vivo and 3D-printed guiding templates in vitro. METHODS The study analyzes the results of 10 surgically treated patients with congenital deformity of the thoracolumbar spine due to vertebrae failure of formation. These patients were included in group 1 (in vivo) comprising six boys and four girls with a mean age of 3 years 8 months (2 years 2 months-6 years 8 month). Group 2 (in vitro) consisted of 27 plastic 3D-printed models of congenitally deformed spine of the same 10 patients in which screws were placed using 3D-printed guiding templates. The accuracy of screw position was assessed using computer tomography data performed postoperatively with Gertzbein-Robbins classification. RESULTS Results of our study show that screw insertion using 3D-printed guiding templates during surgical treatment of infants with congenital spine deformities is more accurate than using freehand technique (96.3% vs. 78.8% p = 0.011). CONCLUSION The data show that this method of screw insertion is very promising and can be used in surgical treatment of infants with congenital spine deformities.
Collapse
|
36
|
Herrera AS, Arias PES, del Carmen Arias Esparza M, Torres Bernal LF, Bondarev AD, Fisenko VP, Chubarev VN, Minyaeva NN, Mikhaleva LM, Tarasov VV, Somasundaram SG, Kirkland CE, Aliev G. Notice of Withdrawal. Curr Top Med Chem 2019; 19:CTMC-EPUB-102353. [PMID: 31724499 DOI: 10.2174/1568026619666191114110928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Revised: 09/05/2019] [Accepted: 10/10/2019] [Indexed: 11/22/2022]
Abstract
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php Bentham Science Disclaimer it is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
Collapse
Affiliation(s)
| | | | | | | | - Andrey D. Bondarev
- I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation
| | - Vladimir P. Fisenko
- I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation
| | - Vladimir N. Chubarev
- I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University),Moscow, Russian Federation
| | - Nina N. Minyaeva
- National Research University Higher School of Economics, 20 Myasnitskaya Street, Moscow, 101000, Russian Federation
| | - Lyudmila M. Mikhaleva
- Research Institute of Human Morphology, 3 Tsyurupy Street, Moscow, 117418, Russian Federation
| | - Vadim V. Tarasov
- I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation
| | | | - Cecil E. Kirkland
- Department of Biological Sciences, Salem University, Salem, WV, United States
| | - Gjumrakch Aliev
- I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation
| |
Collapse
|
37
|
Xiong W, Gasparian A, Gao H, Dutta D, Khandaker M, Liyanage N, Pasyuk E, Peng C, Bai X, Ye L, Gnanvo K, Gu C, Levillain M, Yan X, Higinbotham DW, Meziane M, Ye Z, Adhikari K, Aljawrneh B, Bhatt H, Bhetuwal D, Brock J, Burkert V, Carlin C, Deur A, Di D, Dunne J, Ekanayaka P, El-Fassi L, Emmich B, Gan L, Glamazdin O, Kabir ML, Karki A, Keith C, Kowalski S, Lagerquist V, Larin I, Liu T, Liyanage A, Maxwell J, Meekins D, Nazeer SJ, Nelyubin V, Nguyen H, Pedroni R, Perdrisat C, Pierce J, Punjabi V, Shabestari M, Shahinyan A, Silwal R, Stepanyan S, Subedi A, Tarasov VV, Ton N, Zhang Y, Zhao ZW. A small proton charge radius from an electron-proton scattering experiment. Nature 2019; 575:147-150. [PMID: 31695211 DOI: 10.1038/s41586-019-1721-2] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Accepted: 09/19/2019] [Indexed: 11/09/2022]
Abstract
Elastic electron-proton scattering (e-p) and the spectroscopy of hydrogen atoms are the two methods traditionally used to determine the proton charge radius, rp. In 2010, a new method using muonic hydrogen atoms1 found a substantial discrepancy compared with previous results2, which became known as the 'proton radius puzzle'. Despite experimental and theoretical efforts, the puzzle remains unresolved. In fact, there is a discrepancy between the two most recent spectroscopic measurements conducted on ordinary hydrogen3,4. Here we report on the proton charge radius experiment at Jefferson Laboratory (PRad), a high-precision e-p experiment that was established after the discrepancy was identified. We used a magnetic-spectrometer-free method along with a windowless hydrogen gas target, which overcame several limitations of previous e-p experiments and enabled measurements at very small forward-scattering angles. Our result, rp = 0.831 ± 0.007stat ± 0.012syst femtometres, is smaller than the most recent high-precision e-p measurement5 and 2.7 standard deviations smaller than the average of all e-p experimental results6. The smaller rp we have now measured supports the value found by two previous muonic hydrogen experiments1,7. In addition, our finding agrees with the revised value (announced in 2019) for the Rydberg constant8-one of the most accurately evaluated fundamental constants in physics.
Collapse
Affiliation(s)
- W Xiong
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - A Gasparian
- North Carolina A&T State University, Greensboro, NC, USA.
| | - H Gao
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - D Dutta
- Mississippi State University, Mississippi State, MS, USA.
| | | | - N Liyanage
- University of Virginia, Charlottesville, VA, USA
| | - E Pasyuk
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - C Peng
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - X Bai
- University of Virginia, Charlottesville, VA, USA
| | - L Ye
- Mississippi State University, Mississippi State, MS, USA
| | - K Gnanvo
- University of Virginia, Charlottesville, VA, USA
| | - C Gu
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - M Levillain
- North Carolina A&T State University, Greensboro, NC, USA
| | - X Yan
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - M Meziane
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - Z Ye
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA.,Argonne National Laboratory, Lemont, IL, USA
| | - K Adhikari
- Mississippi State University, Mississippi State, MS, USA
| | - B Aljawrneh
- North Carolina A&T State University, Greensboro, NC, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, MS, USA
| | - D Bhetuwal
- Mississippi State University, Mississippi State, MS, USA
| | - J Brock
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - V Burkert
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - C Carlin
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - A Deur
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - D Di
- University of Virginia, Charlottesville, VA, USA
| | - J Dunne
- Mississippi State University, Mississippi State, MS, USA
| | - P Ekanayaka
- Mississippi State University, Mississippi State, MS, USA
| | - L El-Fassi
- Mississippi State University, Mississippi State, MS, USA
| | - B Emmich
- Mississippi State University, Mississippi State, MS, USA
| | - L Gan
- University of North Carolina, Wilmington, NC, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov, Ukraine
| | - M L Kabir
- Mississippi State University, Mississippi State, MS, USA
| | - A Karki
- Mississippi State University, Mississippi State, MS, USA
| | - C Keith
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - S Kowalski
- Massachusetts Institute of Technology, Cambridge, MA, USA
| | | | - I Larin
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute", Moscow, Russia.,University of Massachusetts, Amherst, MA, USA
| | - T Liu
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | | | - J Maxwell
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | | | - V Nelyubin
- University of Virginia, Charlottesville, VA, USA
| | - H Nguyen
- University of Virginia, Charlottesville, VA, USA
| | - R Pedroni
- North Carolina A&T State University, Greensboro, NC, USA
| | - C Perdrisat
- College of William and Mary, Williamsburg, VA, USA
| | - J Pierce
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - V Punjabi
- Norfolk State University, Norfolk, VA, USA
| | - M Shabestari
- Mississippi State University, Mississippi State, MS, USA
| | | | - R Silwal
- Massachusetts Institute of Technology, Cambridge, MA, USA
| | - S Stepanyan
- Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - A Subedi
- Mississippi State University, Mississippi State, MS, USA
| | - V V Tarasov
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute", Moscow, Russia
| | - N Ton
- University of Virginia, Charlottesville, VA, USA
| | - Y Zhang
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| | - Z W Zhao
- Duke University and Triangle Universities Nuclear Laboratory, Durham, NC, USA
| |
Collapse
|
38
|
Klochkov SG, Pukhov SA, Afanasieva SV, Neganova ME, Ananiev IV, Avila-Rodriguez M, Tarasov VV, Aliev G. A Novel Heterocyclic System Based on Natural Epoxyalantolactone. Front Chem 2019; 7:655. [PMID: 31632949 PMCID: PMC6779722 DOI: 10.3389/fchem.2019.00655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2019] [Accepted: 09/13/2019] [Indexed: 11/29/2022] Open
Abstract
Natural sesquiterpene lactones which contain an exocyclic methylene group in the β-position of the lactone ring react readily with N-nucleophiles. When studying the reaction of the natural epoxyalantolactone with the primary amines we demonstrate the formation of a new heterocyclic system—the hydrogenated benzo[g]furo[4,3,2-cd]indol-3(1H)-one. Spectral data on the characteristics of the synthesized compounds are presented. The data on the reaction mechanisms and its applicability for the preparation are discussed.
Collapse
Affiliation(s)
- Sergey G Klochkov
- Institute of Physiologically Active Compounds of Russian Academy of Sciences, Chernogolovka, Russia
| | - Sergey A Pukhov
- Institute of Physiologically Active Compounds of Russian Academy of Sciences, Chernogolovka, Russia
| | - Svetlana V Afanasieva
- Institute of Physiologically Active Compounds of Russian Academy of Sciences, Chernogolovka, Russia
| | - Margarita E Neganova
- Institute of Physiologically Active Compounds of Russian Academy of Sciences, Chernogolovka, Russia
| | - Ivan V Ananiev
- Institute of Organoelement Compounds of Russian Academy of Sciences, Moscow, Russia
| | - Marco Avila-Rodriguez
- Clinic Sciences Department, Health Sciences Faculty, University of Tolima, Ibagué, Colombia
| | - Vadim V Tarasov
- Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Gjumrakch Aliev
- Institute of Physiologically Active Compounds of Russian Academy of Sciences, Chernogolovka, Russia.,Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.,GALLY International Research Institute, San Antonio, TX, United States
| |
Collapse
|
39
|
Herrera AS, A Esparza MDC, Arias PES, Ashraf GM, Mosa OF, Fisenko VP, Sologova SS, Dostdar SA, Sokolov AV, Bovina EV, Chubarev VN, Tarasov VV, Somasundaram SG, Kirkland CE, Aliev G. The Role of Melanin to Dissociate Oxygen from Water to Treat Retinopathy of Prematurity. Cent Nerv Syst Agents Med Chem 2019; 19:215-222. [PMID: 31267880 DOI: 10.2174/1871524919666190702164206] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Revised: 06/14/2019] [Accepted: 06/17/2019] [Indexed: 11/22/2022]
Abstract
BACKGROUND Retinopathy of Prematurity (ROP) is a potentially blinding disorder that commonly afflicts premature infants who are born prior to 31weeks of gestation or with a body weight less than 1250 grams (about 2.75 pounds). Another risk factor is excessive oxygen in incubators, which can lead to blindness. A compounding factor is that survival rates for premature infants are rising with concomitantly more cases of ROP. We have reported an unsuspected intrinsic property of melanin to dissociate water. This capability can be considered an alternative treatment option for adult and neonatal diseases. It is known that exogenous surfactant administration suppresses bronchopulmonary dysplasia and consequent death, randomized, controlled trials with various respiratory interventions did not show any significant reductions in morbidity and mortality rates. During a descriptive study about the three leading causes of blindness in the world, the ability of melanin to transform light energy into chemical energy through the dissociation of water molecule was unraveled. Initially, during 2 or 3 years; we tried to link together our findings with the widely accepted metabolic pathways already described in molecular pathway databases, which have been developed to collect and organize the current knowledge on metabolism scattered across a multitude of scientific evidence. OBSERVATIONS The current report demonstrates the main problems that afflict premature babies with an emphasis on the growth of abnormal vessels in the retina, the explanation for which is unknown until date. We also reported a case of a baby who suffered digestive and respiratory problems with a brain haemorrhage that was successfully treated by laser photocoagulation. We hypothesise that most likely this effect was due to the melanin level and melanin itself produces oxygen via dissociating with water molecules. CONCLUSION We postulate that the intrinsic effect of melanin may easily convert visible and invisible light into chemical energy via a water dissociation reaction similar to the one in plant's chlorophyll, and markedly elevated with diagnosis and treatment of the complications related to premature babies.
Collapse
Affiliation(s)
- Arturo S Herrera
- Human Photosynthesis® Study Center. Sierra del Laurel 212, Bosques del Prado Norte, Aguascalientes, CP 20000, Mexico
| | - María Del Carmen A Esparza
- Human Photosynthesis® Study Center. Sierra del Laurel 212, Bosques del Prado Norte, Aguascalientes, CP 20000, Mexico
| | - Paola E S Arias
- Human Photosynthesis® Study Center. Sierra del Laurel 212, Bosques del Prado Norte, Aguascalientes, CP 20000, Mexico
| | - Ghulam M Ashraf
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Osama F Mosa
- Health Sciences College at Leith, UQU, Saudi Arabia
| | - Vladimir P Fisenko
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, bld. 2, Moscow, 119991, Russian Federation
| | - Susanna S Sologova
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, bld. 2, Moscow, 119991, Russian Federation
| | - Samira A Dostdar
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, bld. 2, Moscow, 119991, Russian Federation
| | - Alexander V Sokolov
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, bld. 2, Moscow, 119991, Russian Federation
| | - Elena V Bovina
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Vladimir N Chubarev
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, bld. 2, Moscow, 119991, Russian Federation
| | - Vadim V Tarasov
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, bld. 2, Moscow, 119991, Russian Federation
| | - Siva G Somasundaram
- Department of Biological Sciences, Salem University, Salem, WV, United States
| | - Cecil E Kirkland
- Department of Biological Sciences, Salem University, Salem, WV, United States
| | - Gjumrakch Aliev
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, bld. 2, Moscow, 119991, Russian Federation.,Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.,GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, United States
| |
Collapse
|
40
|
Mishchenko DV, Neganova ME, Klimanova EN, Sashenkova TE, Klochkov SG, Shevtsova EF, Vystorop IV, Tarasov VV, Chubarev VN, Samsonova AN, Ashraf GM, Barreto G, Yarla NS, Aliev G. Chemosensitizing Activity of Histone Deacetylases Inhibitory Cyclic Hydroxamic Acids for Combination Chemotherapy of Lymphatic Leukemia. Curr Cancer Drug Targets 2019; 18:365-371. [PMID: 28669342 DOI: 10.2174/1568009617666170623104030] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2017] [Revised: 05/17/2017] [Accepted: 05/31/2017] [Indexed: 11/22/2022]
Abstract
BACKGROUND Anti-tumor effect of hydroxamic acid derivatives is largely connected with its properties as efficient inhibitors of histone deacetylases, and other metalloenzymes involved in carcinogenesis. OBJECTIVE The work was aimed to (i) determine the anti-tumor and chemosensitizing activity of the novel racemic spirocyclic hydroxamic acids using experimental drug sensitive leukemia P388 of mice, and (ii) determine the structure-activity relationships as metal chelating and HDAC inhibitory agents. METHOD Outbreed male rat of 200-220 g weights were used in biochemical experiments. In vivo experiments were performed using the BDF1 hybrid male mice of 22-24 g weight. Lipid peroxidation, Fe (II) -chelating activity, HDAC fluorescent activity, anti-tumor and anti-metastatic activity, acute toxicity techniques were used in this study. RESULTS Chemosensitizing properties of water soluble cyclic hydroxamic acids (CHA) are evaluated using in vitro activities and in vivo methods and found significant results. These compounds possess iron (II) chelating properties, and slightly inhibit lipid peroxidation. CHA prepared from triacetonamine (1a-e) are more effective Fe (II) ions cheaters, as compared to CHA prepared from 1- methylpiperidone (2a-e). The histone deacetylase (HDAC) inhibitory activity, lipophilicity and acute toxicity were influenced by the length amino acids (size) (Glycine < Alanine < Valine < Leucine < Phenylalanine). All compounds bearing spiro-N-methylpiperidine ring (2a-e) are non-toxic up to 1250 mg/kg dose, while compounds bearing spiro-tetramethylpiperidine ring (1a-e) exhibit moderate toxicity which increases with increasing lipophility, but not excite at 400 mg/kg. CONCLUSION It was shown that the use of combination of non-toxic doses of cisplatin (cPt) or cyclophosphamide with CHA in most cases result in the appearance of a considerable anti-tumor effect of cytostatics. The highest chemosensitizing activity with respect to leukemia Р388 is demonstrated by the CHA derivatives of Valine 1c or 2c.
Collapse
Affiliation(s)
- Denis V Mishchenko
- Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.,Moscow Region State University, 105005, Moscow, Russian Federation
| | - Margarita E Neganova
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Elena N Klimanova
- Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Tatyana E Sashenkova
- Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Sergey G Klochkov
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Elena F Shevtsova
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Igor V Vystorop
- Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Vadim V Tarasov
- Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation
| | - Vladimir N Chubarev
- Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation
| | - Anna N Samsonova
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Ghulam Md Ashraf
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - George Barreto
- Departamento de Nutricion y Bioquimica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogota D.C., Colombia.,Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile
| | - Nagendra Sastry Yarla
- GALLY International Biomedical Research Institute Inc., 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, United States
| | - Gjumrakch Aliev
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.,Departamento de Nutricion y Bioquimica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogota D.C., Colombia.,Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile.,GALLY International Biomedical Research Institute Inc., 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, United States
| |
Collapse
|
41
|
Majchrzak M, Brzecka A, Daroszewski C, Błasiak P, Rzechonek A, Tarasov VV, Chubarev VN, Kurinnaya AS, Melnikova TI, Makhmutova A, Klochkov SG, Somasundaram SG, Kirkland CE, Aliev G. Increased Pain Sensitivity in Obese Patients After Lung Cancer Surgery. Front Pharmacol 2019; 10:626. [PMID: 31258474 PMCID: PMC6586739 DOI: 10.3389/fphar.2019.00626] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Accepted: 05/15/2019] [Indexed: 12/13/2022] Open
Abstract
Background: Obesity and cancer are recognized worldwide health threats. While there is no reported causal relationship, the increasing frequency of both conditions results in a higher incidence of obese patients who are being treated for cancer. Physiological data indicate that there is a relationship between obesity and susceptibility to pain; however, currently, there are no specific pharmacological interventions. Objective: To evaluate the self-reported intensity of postoperative pain in obese and nonobese lung cancer who receive either thoracotomy or video-assisted thoracic surgery (VATS) surgical therapy. Material and Methods: In 50 obese [mean body mass index (BMI) of 34.1 ± 3.2 kg/m2] and 62 nonobese (mean BMI of 24.9 ± 3 kg/m2) lung cancer patients, the intensity of pain was estimated every 4 h using a visual analog scale (VAS, 0 indicating no pain and 10 indicating “worst imaginable pain”) beginning shortly after surgery (Day O) and continuing until the day of discharge (Day D). Results: The self-reported pain was more severe in obese than in nonobese patients, both at the time of the operation [Day O (4.5 ± 1.2 vs 3.4 ± 1.1; p < 0.0001)] and at the day of discharge [Day D (3.9 ± 1.4 vs 2.6 ± 0.9, p < 0.0001)]. This finding was consistent both in the patients after thoracotomy and after video-assisted thoracic surgery (VATS, p < 0.0001). The patients with severe pain shortly after surgery (VAS score >4) had significantly higher BMI (31.8 ± 5.6 kg/m2vs 28.8 ± 5.2 kg/m2, p < 0.01) and were hospitalized longer than the remaining patients (13.0 ± 13.6 days vs 9.5 ± 3.6 days, p < 0.05). Conclusion: The reported perception of pain in obese lung cancer patients is greater than in nonobese patients undergoing the same thoracic surgery. In obese patients, severe pain persisted longer. Pain management is an important consideration in the postoperative care of lung cancer patients, even more so with obese patients.
Collapse
Affiliation(s)
- Maciej Majchrzak
- Department of Thoracic Surgery, Medical University in Wroclaw, Wroclaw, Poland
| | - Anna Brzecka
- Department of Pulmonology and Lung Cancer, Medical University in Wroclaw, Wroclaw, Poland
| | - Cyryl Daroszewski
- Department of Pulmonology and Lung Cancer, Medical University in Wroclaw, Wroclaw, Poland
| | - Piotr Błasiak
- Department of Thoracic Surgery, Medical University in Wroclaw, Wroclaw, Poland
| | - Adam Rzechonek
- Department of Thoracic Surgery, Medical University in Wroclaw, Wroclaw, Poland
| | - Vadim V Tarasov
- Department of Pharmacology and Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Vladimir N Chubarev
- Department of Pharmacology and Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Anastasiya S Kurinnaya
- Department of Pharmacology and Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Tatiana I Melnikova
- Department of Pharmacology and Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
| | - Alfiya Makhmutova
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Russia
| | - Sergey G Klochkov
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Russia
| | - Siva G Somasundaram
- Department of Biological Sciences, Salem University, Salem, WV, United States
| | - Cecil E Kirkland
- Department of Biological Sciences, Salem University, Salem, WV, United States
| | - Gjumrakch Aliev
- Department of Pharmacology and Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.,Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Russia.,GALLY International Biomedical Research Institute, San Antonio, TX, United States
| |
Collapse
|
42
|
Aliev G, Ashraf GM, Tarasov VV, Chubarev VN, Leszek J, Gasiorowski K, Makhmutovа A, Baeesa SS, Avila-Rodriguez M, Ustyugov AA, Bachurin SO. Alzheimer's Disease - Future Therapy Based on Dendrimers. Curr Neuropharmacol 2019; 17:288-294. [PMID: 30227819 PMCID: PMC6425077 DOI: 10.2174/1570159x16666180918164623] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Revised: 08/03/2018] [Accepted: 09/17/2018] [Indexed: 11/22/2022] Open
Abstract
Alzheimer’s disease (AD) is characterized by the loss of neurons. It is the most common cause of dementia in the elderly population accompanied by pathological degeneration of neurofibrillary tangles. Senile plaques are formed with beta-amyloid, hyperphosphoryled tau protein, apo-lipoprotein E and presenilin associated with protease activity [amyloid beta (Aβ), gamma-secretase (γS)]. The molecular mechanisms of neurodegeneration include apoptosis, oxidative stress (free radical generation), inflammation, immune activa-tion, and others. The lack of effective treatments for AD stems mainly from the incomplete understanding the causes of AD. Currently, there are several hypotheses explaining the early mechanisms of AD pathogenesis. Recent years witnessed an un-precedented research growth in the area of nanotechnology, which uses atomic, molecular and macromolecular methods to create products in microscale (nanoscale) dimensions. In this article, we have discussed the role of nanotechnology in the de-velopment and improvement of techniques for early diagnosis and effective treatment of AD. Since AD pathology is practi-cally irreversible, applications of disease-modifying treatments could be successful only if early diagnosis of AD is available. This review highlights various possibilities for the early diagnosis and therapy of AD and investigates potential adaptation of nanoparticles-dendrimers as a class of well-defined branched polymers that are chemically synthesized with a well-defined shape, size and nanoscopic physicochemical properties reminiscent of the proteins for the treatment of neurodegenerative diseases.
Collapse
Affiliation(s)
- Gjumrakch Aliev
- GALLY International Biomedical Research Consulting LLC., 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, United States.,School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, United States.,Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Moscow Region, Chernogolovka, 142432, Russian Federation.,Sechenov University, 119991, Moscow, Russian Federation
| | - Ghulam Md Ashraf
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | | | | | - Jerzy Leszek
- Department of Psychiatry, Wroclaw Medical University, 50-367 Wrocław, Poland
| | - Kazimierz Gasiorowski
- Department of Basic Medical Sciences, Wroclaw Medical University, 50-556 Wroclaw, Poland
| | - Alfiya Makhmutovа
- Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Moscow Region, Chernogolovka, 142432, Russian Federation
| | - Saleh Salem Baeesa
- Division of Neurosurgery, College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Marco Avila-Rodriguez
- Departamento de Ciencias Clínicas, Facultad de Ciencias de la Salud, Universidad del Tolima, Colombia
| | - Aleksey A Ustyugov
- Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Moscow Region, Chernogolovka, 142432, Russian Federation
| | - Sergey O Bachurin
- Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Moscow Region, Chernogolovka, 142432, Russian Federation
| |
Collapse
|
43
|
Klochkov SG, Neganova ME, Yarla NS, Parvathaneni M, Sharma B, Tarasov VV, Barreto G, Bachurin SO, Ashraf GM, Aliev G. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy. Semin Cancer Biol 2019; 56:128-134. [DOI: 10.1016/j.semcancer.2017.10.010] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Revised: 10/14/2017] [Accepted: 10/30/2017] [Indexed: 12/20/2022]
|
44
|
Svistunov AA, Tarasov VV, Shakhmardanova SA, Sologova SS, Bagaturiya ET, Chubarev VN, Galenko-Yaroshevsky PA, Avila-Rodriguez MF, Barreto GE, Aliev G. Urotensin II: Molecular Mechanisms of Biological Activity. Curr Protein Pept Sci 2019; 19:924-934. [PMID: 28875851 DOI: 10.2174/1389203718666170829162335] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 07/01/2017] [Accepted: 07/18/2017] [Indexed: 12/12/2022]
Abstract
Urotensin II (UT II) is an important factor of cellular homeostasis. This regulatory peptide is involved in the pathophysiology of many disorders. For example, it plays an important role in the pathogenesis of acute and chronic diseases, stressful and adaptive reactions of the body, in the development of cardiovascular pathologies, metabolic syndrome, inflammation, liver cirrhosis, renal failure, diabetic nephropathy, reproductive dysfunction, progression of psychosomatic, psychoendocrinal and psychiatric disorders. In this concern, the involvement of UT II in the pathophysiology of many processes determines the perspectives for the development of blockers of urotensin receptors for the treatment of the aforementioned diseases. It is important that even today this kind of perspective is feasible due to the synthesis of a series of GPR14 blockers. The objective of this review is to discuss current molecular mechanisms of biological activity, regulatory functions of UT II, its role in the pathogenesis of different nosologies, as well as analysis of the possible routes of exposure to GPR14 as potential therapeutic targets.
Collapse
Affiliation(s)
- Andrey A Svistunov
- Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 19991 Moscow, Russian Federation
| | - Vadim V Tarasov
- Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 19991 Moscow, Russian Federation
| | - Svetlana A Shakhmardanova
- Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 19991 Moscow, Russian Federation
| | - Susanna S Sologova
- Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 19991 Moscow, Russian Federation
| | - Ekaterina T Bagaturiya
- Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 19991 Moscow, Russian Federation
| | - Vladimir N Chubarev
- Institute of Pharmacy and Translational Medicine, Sechenov First Moscow State Medical University, 19991 Moscow, Russian Federation
| | | | - Marco Fidel Avila-Rodriguez
- Facultad de Ciencias de la Salud- Departamento de Ciencias Clínicas- Universidad del Tolima, Ibague, Colombia
| | - George E Barreto
- Departamento de Nutricion y Bioquimica, Facultad de Ciencias, Pontificia Universidad Javeriama, Bogota D.C., Colombia.,Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile
| | - Gjumrakch Aliev
- GALLY International Biomedical Research Consulting LLC., 7733, Louis Pasteur, Drive, #330, San Antonio, TX, 78229, United States.,School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, United States.,Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| |
Collapse
|
45
|
Tarasov VV, Chubarev VN, Ashraf GM, Dostdar SA, Sokolov AV, Melnikova TI, Sologova SS, Grigorevskich EM, Makhmutovа A, Kinzirsky AS, Klochkov SG, Aliev G. How Cancer Cells Resist Chemotherapy: Design and Development of Drugs Targeting Protein-Protein Interactions. Curr Top Med Chem 2019; 19:394-412. [DOI: 10.2174/1568026619666190305130141] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2018] [Revised: 09/20/2018] [Accepted: 11/15/2018] [Indexed: 02/07/2023]
Abstract
Background:Resistance toward chemotherapeutics is one of the main obstacles on the way to effective cancer treatment. Personalization of chemotherapy could improve clinical outcome. However, despite preclinical significance, most of the potential markers have failed to reach clinical practice partially due to the inability of numerous studies to estimate the marker’s impact on resistance properly.Objective:The analysis of drug resistance mechanisms to chemotherapy in cancer cells, and the proposal of study design to identify bona fide markers.Methods:A review of relevant papers in the field. A PubMed search with relevant keywords was used to gather the data. An example of a search request: drug resistance AND cancer AND paclitaxel.Results:We have described a number of drug resistance mechanisms to various chemotherapeutics, as well as markers to underlie the phenomenon. We also proposed a model of a rational-designed study, which could be useful in determining the most promising potential biomarkers.Conclusion:Taking into account the most reasonable biomarkers should dramatically improve clinical outcome by choosing the suitable treatment regimens. However, determining the leading biomarkers, as well as validating of the model, is a work for further investigations.
Collapse
Affiliation(s)
- Vadim V. Tarasov
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russian Federation
| | - Vladimir N. Chubarev
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russian Federation
| | - Ghulam Md Ashraf
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Samira A. Dostdar
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russian Federation
| | - Alexander V. Sokolov
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russian Federation
| | - Tatiana I. Melnikova
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russian Federation
| | - Susanna S. Sologova
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russian Federation
| | - Ekaterina M. Grigorevskich
- Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russian Federation
| | - Alfiya Makhmutovа
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Alexander S. Kinzirsky
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Sergey G. Klochkov
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Gjumrakch Aliev
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| |
Collapse
|
46
|
Aliev G, Li Y, Chubarev VN, Lebedeva SA, Parshina LN, Trofimov BA, Sologova SS, Makhmutova A, Avila-Rodriguez MF, Klochkov SG, Galenko-Yaroshevsky PA, Tarasov VV. Application of Acyzol in the Context of Zinc Deficiency and Perspectives. Int J Mol Sci 2019; 20:E2104. [PMID: 31035445 PMCID: PMC6539662 DOI: 10.3390/ijms20092104] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 04/22/2019] [Accepted: 04/24/2019] [Indexed: 12/23/2022] Open
Abstract
Zinc is one of the most important essential trace elements. It is involved in more than 300 enzyme systems and is an indispensable participant in many biochemical processes. Zinc deficiency causes a number of disorders in the human body, the main ones being the delay of growth and puberty, immune disorders, and cognitive dysfunctions. There are over two billion people in the world suffering from zinc deficiency conditions. Acyzol, a zinc-containing medicine, developed as an antidote against carbon monoxide poisoning, demonstrates a wide range of pharmacological activities: Anti-inflammatory, reparative, detoxifying, immunomodulatory, bacteriostatic, hepatoprotective, adaptogenic, antioxidant, antihypoxic, and cardioprotective. The presence of zinc in the composition of Acyzol suggests the potential of the drug in the treatment and prevention of zinc deficiency conditions, such as Prasad's disease, immune system pathology, alopecia, allergodermatoses, prostate dysfunction, psoriasis, stomatitis, periodontitis, and delayed mental and physical development in children. Currently, the efficiency of Acyzol in the cases of zinc deficiency is shown in a large number of experimental studies. So, Acyzol can be used as a highly effective drug for pharmacologic therapy of a wide range of diseases and conditions and it opens up new perspectives in the treatment and prevention of zinc deficiency conditions.
Collapse
Affiliation(s)
- Gjumrakch Aliev
- Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia.
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia.
- GALLY International Research Institute, 7733 Louis Pasteur Drive #330, San Antonio, TX 78229, USA.
| | - Yi Li
- Department of Biological and Health Sciences, Texas A&M University-Kingsville, TX 78363, USA.
| | - Vladimir N Chubarev
- Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia.
| | - Svetlana A Lebedeva
- Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia.
| | - Lidiya N Parshina
- A.E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, 1 Favorsky Str., Irkutsk 664033, Russia.
| | - Boris A Trofimov
- A.E. Favorsky Irkutsk Institute of Chemistry, Siberian Branch of the Russian Academy of Sciences, 1 Favorsky Str., Irkutsk 664033, Russia.
| | - Susanna S Sologova
- Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia.
| | - Alfiya Makhmutova
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia.
| | - Marco F Avila-Rodriguez
- Universidad del Tolima, Facultad de Ciencias de la Salud, Barrio Santa Helena, Ibagué 730006, Colombia.
| | - Sergey G Klochkov
- Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia.
| | - Pavel A Galenko-Yaroshevsky
- Department of Pharmacology, Faculty of Pharmacy, Kuban State Medical University, 4 Sedin St., Krasnodar 350063, Russia.
| | - Vadim V Tarasov
- Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia.
| |
Collapse
|
47
|
Makara-Studzińska M, Madej A, Trypka E, Leszek J, Tarasov VV, Ashraf GM, Yarla NS, Samsonova AN, Aliev G. Quality of Life and Social Support in Women with Urinary Incontinence. CWHR 2019. [DOI: 10.2174/1573404814666180125160956] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Urinary incontinence (UI) is a serious medical and social problem for
about one-third of women in the world population. It is one of the most common chronic diseases of
women. Despite significant improvement in the diagnosis and treatment of this illness, women continue
to struggle with the stigma associated with incontinence. Research conducted in the last few
years shows the importance of social support in respect of the illness.
Aim:
The purpose of this study was to determine how people perceive the disease and the influence
of social support to deal with UI.
Materials and Methods:
The study involved 200 women in the age range of 34-78 with a diagnosis
of incontinence. All women agreed to fill out an anonymous questionnaire, Acceptance of Illness
Scale (AIS) and Disease-Related Social Support Scale (DSRSS). The obtained results were subject
to statistical analysis.
Results:
The greater the social support, the lesser the tendencies to judge the condition in terms of
harm. Material support among respondents makes it easier for them to distance themselves from UI.
Women having a sense of spiritual, emotional, and global support information found it easier to
come in terms with UI.
Conclusion:
There is a relationship between the perception of disease for women, and social support
received by women. Awareness of the availability support in disease allows peaceful thinking
about a situation as difficult as UI.
Collapse
Affiliation(s)
| | - Agata Madej
- Department of Applied Psychology, Medical University of Lublin, Lublin, Poland
| | - Elżbieta Trypka
- Department of Psychiatry, Wroclaw Medical University, Wroclaw, Poland
| | - Jerzy Leszek
- Department of Psychiatry, Wroclaw Medical University, Wroclaw, Poland
| | - Vadim V. Tarasov
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8, Bld. 2, Moscow, 119991, Russian Federation
| | - Ghulam M. Ashraf
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Nagendra Sastry Yarla
- GALLY International Biomedical Research Consulting LLC., 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, United States
| | - Anna N. Samsonova
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Gjumrakch Aliev
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| |
Collapse
|
48
|
Putta S, Yarla NS, Kumar K E, Lakkappa DB, Kamal MA, Scotti L, Scotti MT, Ashraf GM, Rao BSB, D SK, Reddy GV, Tarasov VV, Imandi SB, Aliev G. Preventive and Therapeutic Potentials of Anthocyanins in Diabetes and Associated Complications. Curr Med Chem 2019; 25:5347-5371. [PMID: 29210634 DOI: 10.2174/0929867325666171206101945] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Revised: 08/30/2016] [Accepted: 09/04/2016] [Indexed: 11/22/2022]
Abstract
Diet is an essential factor affecting the development of and risk for diabetes mellitus. In search of preventative and therapeutic strategies, the potential role of certain foods and their bioactive compounds to prevent the pathogenesis associated with metabolic diseases is to be considered. Human consumption of anthocyanins is among the highest of all flavonoids. Epidemiological studies have suggested that the consumption of anthocyanins lowers the risk of diabetes and diabetic complications. Anthocyanins are important natural bioactive pigments responsible for red to blue colour of fruits, leaves, seeds, stems and flowers, which are present in a variety of plant species particularly in berries and cherries. A large number of bioactive anthocyanins, such as cyanidin, malvidin, delphinidin, pelargonidin, peonidin, petunidin and their metabolites have shown multiple biological activities with apparent effects on glucose absorption, glucose uptake, insulin secretion and sensitivity, on the enzymes involved in glucose metabolism, gene expressions, inflammatory mediators, glucose transporters in progression of diabetes and associated complications, such as diabetic retinopathy, nephropathy, neuropathy and diabetic vascular diseases. The versatility of the anthocyanins provides a promising approach for diabetes management than synthetic drugs. Here we summarize the effect of several anthocyanins on many in vitro, in vivo and clinical studies and also reveal the mechanisms which could prevent or reverse the underlying mechanisms of diabetic pathologies including promotion of antioxidant, antihyperlipidemic, anti-inflammatory and anti-apoptotic activities.
Collapse
Affiliation(s)
- Swathi Putta
- Pharmacology division, University College of Pharmaceutical Sciences, Andhra University, Visakhapatnam- 530003, Andhra Pradesh, India
| | - Nagendra Sastry Yarla
- Department of Biochemistry, Institute of Science, GITAM University, Vishakhapatnam-530045, A.P, India
| | - Eswar Kumar K
- Pharmacology division, University College of Pharmaceutical Sciences, Andhra University, Visakhapatnam- 530003, Andhra Pradesh, India
| | - Dhananjaya Bhadrapura Lakkappa
- Toxinology/Toxicology and Drug Discovery Unit, Center for Emerging Technologies, Jain Global Campus, Jain University, Ramanagara-562 112, Karnataka, India
| | - Mohammad A Kamal
- Metabolomics & Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia.,Novel Global Community Educational Foundation, 7 Peterlee Place, Hebersham, NSW 2770, Australia
| | - Luciana Scotti
- Federal University of Paraiba, Campus I 58051-970, Joao Pessoa, PB, Brazil
| | - Marcus T Scotti
- Federal University of Paraiba, Campus I 58051-970, Joao Pessoa, PB, Brazil
| | - Ghulam Md Ashraf
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - B Sasi Bhusana Rao
- Department of Biochemistry, Sri Krishnadevaraya University, Anantapuramu- 515 003(A.P), India
| | - Sarala Kumari D
- Department of Biochemistry, Sri Krishnadevaraya University, Anantapuramu- 515 003(A.P), India
| | - Gorla V Reddy
- Department of Animal Biology, School of Life Sciences, University of Hyderabad, Hyderabad 500 046, India
| | - Vadim V Tarasov
- Department of Pharmacology of Pharmaceutical Faculty, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | - Sarat Babu Imandi
- Department of Biotechnology, Institute of Technology, GITAM University, Vishakhapatnam-530045, A.P., India
| | - Gjumrakch Aliev
- Department of Pharmacology of Pharmaceutical Faculty, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.,"GALLY" International Biomedical Research Consulting LLC, San Antonio, TX 78229, United States.,School of Health Sciences and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, United States.,Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| |
Collapse
|
49
|
Carrera I, Fernandez-Novoa L, Sampedro C, Tarasov VV, Aliev G, Cacabelos R. Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease. Curr Med Chem 2019; 25:5372-5388. [PMID: 29637853 DOI: 10.2174/0929867325666180410100559] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2016] [Revised: 10/02/2017] [Accepted: 02/24/2018] [Indexed: 11/22/2022]
Abstract
Patients with Parkinson's disease (PD) are looking forward to new therapeutic strategies that may gradually decelerate the rate of neurodegenerative decline, associated with mobility restrictions and related morbidity. Its continuous neurodegenerative process, exacerbated by genetic mutations or environmental toxins, involves a progressive reduction in the dopamine neurotransmission levels, synaptic uptake density, oxidative glucose intake, deficient striatal lactate accumulation and chronic inflammation. Over the last decade, novel bioproducts have received considerable interest due to their unique potential of unifying nutritional, safety and therapeutic natural effects. Some nutraceuticals play a crucial role in the control of the signaling transduction pathways in neurotransmission and inflammation affected in PD, and some natural compounds can beneficially interact with each one of these biological mechanisms to slow down disease progression. Atremorine, a novel plant-derived nutraceutical, probably with a neuroprotective effect in the dopaminergic neurons of the substantia nigra (pars compacta), is a prototype of this new category of bioproducts with potential effects in PD. The major focus of this review will be on the current knowledge and biomedical investigation strategies through a plant-derived neuroprotective approach to improve life quality in PD patients, being of paramount importance for health providers, caregivers and the patients themselves.
Collapse
Affiliation(s)
- Ivan Carrera
- Health Biotechnology, EuroEspes Biotechnology, Corunna, Spain.,Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation
| | | | | | - Vadim V Tarasov
- Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation
| | - Gjumrakch Aliev
- Gally International Biomedical Research LLC, San Antonio, Texas, United States.,University of Atlanta, John Greek , GA, United States.,Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| | - Ramon Cacabelos
- EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Corunna, Spain
| |
Collapse
|
50
|
Leszek J, Trypka E, Koutsouraki E, Michmizos D, Yarla NS, Tarasov VV, Ashraf GM, Aliev G. Late-life Depression and Alzheimer Disease: A Potential Synergy of the Underlying Mechanisms. Curr Med Chem 2019; 25:5389-5394. [PMID: 27593962 DOI: 10.2174/0929867323666160902152829] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2016] [Revised: 06/25/2016] [Accepted: 07/13/2016] [Indexed: 11/22/2022]
Abstract
A number of biological and clinical characteristics typical of late life depression (LLD) have been suggested by recent research findings. The close association of LLD with cognitive impairment is now well documented and evidenced. However, it is still not clear whether it is depression that leads to cognitive decline, and in more severe cases, to dementia. The work presented in this review article suggests that depression and dementia frequently and strongly copresent, even if the causality remains largely opaque.
Collapse
Affiliation(s)
- Jerzy Leszek
- Department of Psychiatry, Wroclaw Medical University, Pasteura 10, Str.,50-368 Wroclaw, Poland
| | - Elżbieta Trypka
- Department of Psychiatry, Wroclaw Medical University, Pasteura 10, Str.,50-368 Wroclaw, Poland
| | | | | | - Nagendra Sastry Yarla
- Department of Biochemistry and Bioinformatics, Institute of Science, GITAM University, Visakhapatnam, Andhra Pradesh, 530045, India
| | - Vadim V Tarasov
- Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation
| | - Ghulam Md Ashraf
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Gjumrakch Aliev
- Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation.,GALLY International Biomedical Research Consulting LLC., 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, United States.,School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, United States.,Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation
| |
Collapse
|